miltefosine has been researched along with Leishmaniasis, Visceral in 328 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sodium antimony gluconate (SAG) and miltefosine used in the treatment of kala-azar are known to cause several side effects but severe thrombocytopenia has not been reported." | 7.74 | Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine. ( Kumar, A; Mitra, G; Thakur, CP; Thakur, M; Thakur, S, 2007) |
| "Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year." | 6.52 | Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. ( Fujinami, N; Shah, PJ; Vakil, NH, 2015) |
| " We reported a case of acute anterior uveitis,a rare adverse effect, experienced by a patient treated with miltefosine for post-kala-azar dermal leishmaniasis." | 5.56 | Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis. ( Das, P; Das, VNR; Lal, CS; Pal, B; Pandey, K; Topno, RK, 2020) |
| " One hundred and fifty patients aged ≥18 years with serologically confirmed HIV and parasitologically confirmed VL were randomly allocated to 1 of 2 treatment arms, either a total 40 mg/kg intravenous liposomal amphotericin B (AmBisome; Gilead Pharmaceuticals) administered in 8 equal doses over 24 days or a total 30 mg/kg intravenous AmBisome administered in 6 equal doses given concomitantly with a total 1." | 5.51 | AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial. ( Alexander, N; Alves, F; Burza, S; Das, P; Das, VNR; de Lima Pereira, A; Gill, N; Goyal, V; Harshana, A; Kazmi, S; Kumar, D; Kumar, V; Lal, CS; Lasry, E; Mahajan, R; Pandey, K; Rewari, B; Rijal, S; Verma, N, 2022) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 5.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Embedded in a clinical trial in Northwest Ethiopia, RNA-Seq was performed on whole blood samples of 28 VL-HIV patients before and after completion of a 29-day treatment regimen of AmBisome or AmBisome/miltefosine." | 5.34 | Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV. ( Adriaensen, W; Alves, F; Blesson, S; Cnops, L; Cordero, CF; Cuypers, B; Diro, E; Kaye, PM; Mengasha, B; van Griensven, J, 2020) |
| "Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the next year, they all suffer from limitations of either cost, specific toxicities or parenteral administration." | 4.83 | Current scenario of drug development for leishmaniasis. ( Croft, SL; Seifert, K; Yardley, V, 2006) |
| "We have previously shown that 3-nitro-1H-1,2,4-triazole-based arylamides and arylsulfonamides demonstrate significant activity in vitro against Trypanosoma cruzi, the causative parasite of Chagas disease." | 3.80 | Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. ( Bloomer, WD; Kaiser, M; Papadopoulou, MV; Rosenzweig, HS; Wilkinson, SR, 2014) |
| "Sodium antimony gluconate (SAG) and miltefosine used in the treatment of kala-azar are known to cause several side effects but severe thrombocytopenia has not been reported." | 3.74 | Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine. ( Kumar, A; Mitra, G; Thakur, CP; Thakur, M; Thakur, S, 2007) |
| " Allometric dosing ensured similar MF exposure in children (<12 years) and adults." | 3.30 | Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial. ( Alcoba, G; Alvar, J; Alves, F; Dorlo, TPC; Egondi, T; Fikre, H; Ismail Omer Haroun, A; Khalil, EAG; Mbui, J; Mekonnen, T; Mersha, D; Mohammed, R; Musa Younis, B; Musa, AM; Muthoni Ouattara, G; Nakanwagi, P; Njenga, S; Nour, A; Olobo, J; Omollo, T; Ritmeijer, K; Sagaki, P; Sisay, K; Solomos, A; Taha Ahmed Elmukashfi, E; Verrest, L; Wasunna, M, 2023) |
| "Paromomycin exposure was lower in paediatric patients compared with adults [median (IQR) end-of-treatment AUC0-24h 187 (162-203) and 242 (217-328) µg·h/mL, respectively], but were both within the IQR of end-of-treatment exposure in Kenyan and Sudanese adult patients from a previous study." | 3.30 | Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis. ( Alves, F; Chu, WY; Dorlo, TPC; Huitema, ADR; Mbui, J; Mohammed, R; Musa, AM; Njenga, S; Olobo, J; Ritmeijer, K; Roseboom, IC; Solomos, A; Verrest, L; Wasunna, M, 2023) |
| " There were 19 treatment-related adverse events (AEs), but none caused treatment discontinuation." | 2.90 | Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial. ( Alvar, J; Alves, F; Dorlo, TPC; Egondi, TW; Kimutai, R; Kip, AE; Kirigi, G; Mbui, J; Olobo, J; Omollo, R; Omollo, T; Sagaki, P; Solomos, A; Wasunna, M; Were, L, 2019) |
| " All three regimens were safe, with 5 severe adverse events in the SDA arm, two of which were considered to be drug related." | 2.87 | Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. ( Alvar, J; Alves, F; Balasegaram, M; Bern, C; Burza, S; Das, P; Ellis, S; Goyal, V; Hightower, A; Lima, N; Mahajan, R; Pandey, K; Rabi Das, VN; Rijal, S; Sharma, B; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T; Topno, RK, 2018) |
| " Combination regimens including AmBisome, paromomycin and miltefosine have proved to be safe and effective in the treatment of VL in India." | 2.84 | Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. ( Alvar, J; Alves, F; Balasegaram, M; Boer, MD; Ellis, S; Faiz, A; Goyal, V; Haque, R; Jamil, K; Rahman, R; Rijal, S; Samad, R; Sharma, B; Strub-Wourgaft, N, 2017) |
| "Miltefosine drug exposure was found to be decreased in Eastern African patients with visceral leishmaniasis, due to a (transient) initial lower bioavailability." | 2.84 | Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. ( Alves, F; Balasegaram, M; Beijnen, JH; Dorlo, TPC; Ellis, SJ; Hailu, A; Karlsson, MO; Khalil, EAG; Kip, AE; Kirigi, G; Musa, AM; Njenga, S; Olobo, J; Wasunna, M; Younis, BM, 2017) |
| " Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa." | 2.82 | Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. ( Alexander, N; Ali, MH; Alves, F; Balasegaram, M; Dorlo, TP; Edwards, T; Elamin, MY; Ellis, S; Hailu, A; Juma, R; Khalil, EA; Kimutai, R; Kip, AE; Kirigi, G; Musa, A; Musa, B; Njenga, S; Olobo, J; Omollo, R; Schoone, GJ; Strub Wourgaft, N; Wasunna, M; Wells, S, 2016) |
| "Miltefosine was extracted from DBS samples using a simple method of pretreatment with methanol, resulting in >97% recovery." | 2.82 | Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection. ( Beijnen, JH; Blesson, S; Diro, E; Dorlo, TP; Hailu, A; Hillebrand, MJ; Kip, AE; Mengesha, B; Rosing, H; Schellens, JH, 2016) |
| "Miltefosine was found to be effective and safe in the treatment of PKDL." | 2.80 | Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. ( Chakravarty, J; Rai, M; Singh, A; Sundar, S, 2015) |
| " We hypothesized that the current linear dosage (in milligrams per kilogram of body weight) is too low for children and that a new dosing algorithm based on an appropriate body size model would result in an optimal exposure." | 2.77 | Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. ( Beijnen, JH; de Vries, PJ; Dorlo, TP; Huitema, AD, 2012) |
| "Combination treatments for visceral leishmaniasis are efficacious and safe, and decrease the duration of therapy, thereby encouraging adherence and reducing emergence of drug-resistant parasites." | 2.76 | Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. ( Alam, S; Arora, R; Balasegaram, M; Chakravarty, J; Das, P; Ellis, S; Kumari, P; Lal, CS; Modabber, F; Nawin, K; Olliaro, P; Pandey, K; Rai, M; Sharma, B; Sinha, PK; Strub-Wourgaft, N; Sundar, S; Vaillant, M; Verma, DK; Verma, N, 2011) |
| "Oral miltefosine is an attractive alternative to intramuscular antimony and intravenous amphotericin B for treatment of kala-azar in Bangladesh." | 2.76 | Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. ( Ahmad, Z; Ahmed, BN; Arana, B; Bangali, AM; Berman, J; Chowdhury, MZ; Faiz, MA; Hossain, M; Islam, MN; Islam, QT; Mascie-Taylor, CG; Rahman, M; Rahman, MR; Sayeedur, R, 2011) |
| " We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported serious adverse events (SAEs)." | 2.72 | Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis. ( Alves, F; Brack, M; Dahal, P; Guerin, PJ; Halleux, CM; Hawryszkiewycz, A; Maguire, BJ; Ngu, R; Olliaro, PL; Rashan, S; Singh-Phulgenda, S; Stepniewska, K, 2021) |
| "Treatment with miltefosine is equally effective as standard SSG treatment in non-HIV-infected men with VL." | 2.72 | A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. ( Assefa, Y; Boots, G; Davidson, RN; Dejenie, A; den Boer, M; Hundie, TB; Mesure, J; Ritmeijer, K, 2006) |
| "Miltefosine has previously been shown to cure 97% of cases of visceral leishmaniasis (VL) in Indian adults." | 2.71 | Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. ( Berman, JD; Bhattacharya, SK; Bryceson, AD; Engel, J; Jha, TK; Junge, K; Karbwang, J; Sindermann, H; Sundar, S; Thakur, CP, 2004) |
| "Miltefosine was well-tolerated." | 2.71 | Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. ( Bachmann, P; Berman, J; Jha, TK; Junge, K; Sindermann, H; Sundar, S, 2003) |
| "Miltefosine is an oral agent that has been shown in small numbers of patients to have a favorable therapeutic index for Indian visceral leishmaniasis." | 2.70 | Oral miltefosine for Indian visceral leishmaniasis. ( Berman, J; Bryceson, A; Engel, J; Fischer, C; Jha, TK; Junge, K; Sindermann, H; Sundar, S; Thakur, CP, 2002) |
| "Treatment with miltefosine at 100-150 mg/day for 4 weeks has promise as an effective oral treatment of visceral leishmaniasis including antimony-resistant infection." | 2.69 | Trial of oral miltefosine for visceral leishmaniasis. ( Goyal, AK; Hilgard, P; Makharia, MK; Mandal, AK; Murray, HW; Rosenkaimer, F; Sundar, S; Voss, A, 1998) |
| "Miltefosine is a phosphocholine analogue that affects cell-signaling pathways and membrane synthesis." | 2.69 | Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. ( Bachmann, P; Berman, J; Fischer, C; Jha, TK; Karbwang, J; Sundar, S; Thakur, CP; Voss, A, 1999) |
| " Descriptive analysis showed that 20% of patients experienced adverse events, which mostly had an onset in the first week of treatment and were likely to get more severe after four weeks of treatment." | 2.61 | The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis. ( den Boer, ML; Essink, DR; Pijpers, J; Ritmeijer, K, 2019) |
| "Visceral leishmaniasis affects 200-400 thousands people annually worldwide." | 2.58 | Visceral Leishmaniasis-Optimum Treatment Options in Children. ( Agarwal, D; Sundar, S, 2018) |
| "Frequent relapses are observed in co-infected HIV who can benefit of a second cycle." | 2.55 | Visceral leishmaniosis in immunocompromised host: an update and literature review. ( Esposito, S; Pagliano, P, 2017) |
| "Visceral leishmaniasis is a serious public health problem on the Indian subcontinent, causing high morbidity and mortality." | 2.53 | Elimination of visceral leishmaniasis on the Indian subcontinent. ( Boelaert, M; Hasker, E; Singh, OP; Sundar, S, 2016) |
| "Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year." | 2.52 | Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. ( Fujinami, N; Shah, PJ; Vakil, NH, 2015) |
| "Several advances in the treatment of visceral leishmaniasis have been accomplished during the past few years." | 2.46 | Visceral leishmaniasis in children: a review. ( Palumbo, E, 2010) |
| "Combination therapy for the treatment of visceral leishmaniasis has increasingly been advocated as a way to increase treatment efficacy and tolerance, reduce treatment duration and cost, and limit the emergence of drug resistance." | 2.46 | Combination therapy for visceral leishmaniasis. ( Alvar, J; Balasegaram, M; Boelaert, M; Lynen, L; Meheus, F; van Griensven, J, 2010) |
| "We report a 46-year-old patient with acquired immune deficiency syndrome who, 7 months after diagnosis of VL, developed PKDL and uveal leishmaniasis following HAART-induced immune recovery." | 2.44 | Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. ( Acquaviva, V; Antinori, S; Bestetti, G; Corbellino, M; Foschi, A; Longhi, E; Meroni, L; Parravicini, C; Piolini, R; Trovati, S, 2007) |
| "Miltefosine is a lecithin analogue and its mechanism may be to inhibit phosphatidylcholine biosynthesis in the causative parasites." | 2.43 | Miltefosine to treat leishmaniasis. ( Berman, J, 2005) |
| "Large-scale antimony resistance in the treatment of visceral leishmaniasis (VL) in north Bihar, India, has led to the development of miltefosine as an alternative therapy." | 2.43 | Oral miltefosine for the treatment of Indian visceral leishmaniasis. ( Bhattacharya, SK; Jha, TK; Rai, M; Sundar, S; Thakur, CP, 2006) |
| "Miltefosine is an alkylphosphocholine, originally developed for the treatment of cancer." | 2.43 | [Miltefosine: a new remedy for leishmaniasis]. ( Beijnen, JH; de Vries, PJ; Dorlo, TP; Eggelte, TA, 2006) |
| "Amphotericin B is a polyene macrolide antibiotic that binds to sterols in cell membranes." | 2.42 | [Visceral leishmaniasis: new drugs]. ( Garnier, JM; Minodier, P; Retornaz, K; Robert, S, 2003) |
| "Visceral leishmaniasis is common in less developed countries, with an estimated 500000 new cases each year." | 2.41 | Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. ( Boelaert, M; Bryceson, AD; Croft, SL; Desjeux, P; Guerin, PJ; Olliaro, P; Sundar, S; Wasunna, MK, 2002) |
| "This report reviews the evolution of treatment of visceral leishmaniasis, considers the interaction of the immune response and chemotherapy, highlights therapeutic successes and failures, examines advantages and disadvantages of current treatments, and looks at future therapeutic approaches to the management of this disseminated intracellular protozoal infection." | 2.41 | Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. ( Murray , HW, 2000) |
| " Following the confirmation of significant in vitro activity, the performance of the maximum tolerated dose of OLPC was evaluated in an experimental murine model of CL followed by a dose-response titration and the efficacy evaluation of four OLPC formulations (two with a fast-release and two with a slow-release profile) using bioluminescent Leishmania major parasites." | 1.91 | Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis. ( Alavijeh, M; Croft, SL; Dixon, J; Harris, A; Mcarthur, KN; Platteeuw, JJ; Van Bocxlaer, K; Van Den Heuvel, D; Yardley, V, 2023) |
| "Canine visceral leishmaniasis is an endemic zoonosis in Brazil." | 1.72 | Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis. ( Almeida, ADBPF; Ayres, EDCBS; Barbosa, MEC; Dias, ÁFLR; Dutra, V; Macedo, LFDC; Monteiro, BRG; Nakazato, L; Pazzini, SS; Silva, EBD; Sousa, VRF, 2022) |
| "Visceral leishmaniasis is a potentially fatal disease caused by the parasitic protists, Leishmania donovani and L." | 1.72 | Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani. ( Ainslie, KM; Bachelder, EM; Baell, J; Das, N; Ganguly, D; Hasan Zahid, MS; Johnson, MM; Koh, D; McConville, M; McNamara, N; No, JH; Patra, B; Roy, J; Saunders, E; Shum, D; Simpson, K; Talukdar, A; Varghese, S; Varma, DM; Zheng, R, 2022) |
| " The aim of this study was to characterise the pharmacokinetic and pharmacodynamic properties of the anti-leishmanial drugs AmBisome and miltefosine in a preclinical disease model of VL." | 1.62 | Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis. ( Angulo-Barturen, I; Coteron-Lopez, JM; Croft, SL; Ferrer-Bazaga, S; Harris, A; Seifert, K; Voak, AA, 2021) |
| " One promising pyridine derivative (49) displayed 100% oral bioavailability in mice and delivered a 96% parasite burden reduction when dosed at 50 mg/kg in a Leishmania donovani mouse model of visceral leishmaniasis." | 1.62 | Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal. ( Braillard, S; Chatelain, E; Cooper, CB; Denny, WA; Franzblau, SG; Gupta, S; Launay, D; Ma, Z; Maes, L; Marshall, AJ; O'Connor, PD; Thompson, AM; Wan, B; Yardley, V, 2021) |
| "Miltefosine was authorized to treat canine leishmaniasis (CanL) in Brazil in 2017, but there is a persistent fear of the emergence of parasites resistant not only to this drug but, through cross-resistance mechanisms, also to meglumine antimoniate and amphotericin B." | 1.62 | Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol. ( Campos, MP; Figueiredo, FB; Gonçalves, AS; Gonçalves, G; Medeiros, LCS, 2021) |
| " We reported a case of acute anterior uveitis,a rare adverse effect, experienced by a patient treated with miltefosine for post-kala-azar dermal leishmaniasis." | 1.56 | Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis. ( Das, P; Das, VNR; Lal, CS; Pal, B; Pandey, K; Topno, RK, 2020) |
| " A 69% lower bioavailability at treatment start was estimated, presumably due to initial malnourishment and malabsorption." | 1.56 | Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa. ( Alves, F; Beijnen, JH; Dorlo, TPC; Kip, AE; Mbui, J; Musa, A; Olobo, J; Palić, S; Solomos, A; Wasunna, M, 2020) |
| "Visceral leishmaniasis is responsible for up to 30,000 deaths every year." | 1.56 | Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. ( Ballard, J; Be, C; Berman, A; Biggart, A; Bursulaya, B; Caridha, D; Chen, YL; Chianelli, D; Davis, LC; Eggimann, FK; Gao, MY; Gibney, M; Glynne, RJ; Groessl, T; Hein, A; Jiricek, J; Johnson, K; Khare, S; Kreishman-Deitrick, M; Lai, YH; Lerario, I; Liang, F; Liu, X; Luneau, A; Mathison, CJN; Molteni, V; Nagle, A; Pybus, B; Rao, SPS; Richmond, W; Rudewicz, PJ; Sciotti, RJ; Shapiro, M; Smith, J; Spraggon, G; Srinivas, H; Supek, F; Thompson, C; Tuntland, T; Wiesmann, C; Xie, Y; Yeh, V, 2020) |
| "When miltefosine was used as proof-of-concept, spleen weight parasite burden and bioluminescence values decreased significantly." | 1.51 | A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery. ( Álvarez-Velilla, R; Balaña-Fouce, R; Fresno, M; Gutiérrez-Corbo, MDC; Pérez-Pertejo, MY; Punzón, C; Reguera, RM, 2019) |
| " This study aimed to investigate the feasibility of using focused pharmacovigilance for VL (VLPV) in Bangladesh's National Kala-azar Elimination Programme for the early detection and prevention of expected and unexpected adverse drug reactions (ADRs)." | 1.48 | Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. ( Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V, 2018) |
| " Long half-life of the molecule was confirmed and differential pattern of accumulation of the drug was observed in analyzed organs in mice and hamster." | 1.48 | Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum. ( Alunda, JM; Corral, MJ; Costi, MP; Escribano, MD; García-Calvo, E; Gutiérrez, C; Jiménez-Antón, MD; Kayali, N; Luque-García, JL; Olías-Molero, AI; Torrado, JJ, 2018) |
| "Miltefosine has been used successfully to treat visceral leishmaniasis (VL) in India, but it was unsuccessful for VL in a clinical trial in Brazil." | 1.48 | A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis. ( Brown, E; Carnielli, JBT; Carvalho, SFG; Costa, CHN; Costa, DL; Crouch, K; Damasceno, JD; Dickens, NJ; Dietze, R; Forrester, S; Jeffares, DC; Mottram, JC; Silva, VC, 2018) |
| " The only orally bioavailable drug miltefosine is toxic and the effective liposomal Amphotericin B (AmBisome) is limited by its prohibitive cost and requirement for parenteral administration." | 1.48 | Lactoferrin-modified Betulinic Acid-loaded PLGA nanoparticles are strong anti-leishmanials. ( Das, S; Halder, A; Mukherjee, A; Roy, P; Saha, B; Shukla, D, 2018) |
| "Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated." | 1.46 | Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. ( Arrese Estrada, J; Cnops, L; Darcis, G; de Leval, L; Giot, JB; Hayette, MP; Leonard, P; Moutschen, M; Tassin, F; Van der Auwera, G, 2017) |
| "To assess the rate of default from treatment in the visceral leishmaniasis (VL) elimination programme and to identify risk factors and its underlying causes." | 1.46 | Risk Factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India. ( Boelaert, M; Chakravarty, J; Hasker, E; Kansal, S; Kumar, A; Malaviya, P; Ostyn, B; Sundar, S, 2017) |
| "Miltefosine therapy was followed by a prolonged secondary prophylaxis with L-AmB in the only 2 cases with sustained clinical response and ongoing immunosuppression." | 1.46 | Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain. ( Aguado, JM; Alonso-Moralejo, R; Andrés, A; Carrasco-Antón, N; Fernández-Ruiz, M; González, E; López-Medrano, F; Pérez-Jacoiste Asín, MA; San Juan, R, 2017) |
| "Miltefosine (MIL) is an oral antileishmanial drug used for treatment of visceral leishmaniasis (VL) in the Indian subcontinent." | 1.46 | Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. ( Bhandari, V; Deep, DK; Dujardin, JC; Ramesh, V; Salotra, P; Sharma, V; Singh, R; Sundar, S; Verma, A; Wajid, S, 2017) |
| "Miltefosine is an oral drug which was used as a topical application for skin metastasis of breast cancer." | 1.43 | Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India. ( Das Gupta, RK; Das, P; Dhariwal, AC; Pandey, K; Ravidas, V; Siddiqui, NA; Singh, TP; Sinha, SK; Verma, RB, 2016) |
| "Visceral leishmaniasis is a severe parasitic disease that is one of the most neglected tropical diseases." | 1.42 | Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity. ( Braillard, S; Brown, AD; Cao, Y; Feijens, PB; Gardner, JM; Gibson, KR; Glossop, PA; Hua, W; Maes, LJ; Matheeussen, A; Mills, JE; Morgans, GL; Mowbray, CE; Speed, W; Whitlock, GA, 2015) |
| "Visceral leishmaniasis is a neglected parasitic disease that has a high fatality rate in the absence of treatment." | 1.42 | SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines. ( Barber, MM; Manetsch, R; Van Horn, KS; Wang, MZ; Werbovetz, KA; Yang, S; Zhu, X, 2015) |
| "In this study 86 confirmed cases of PKDL were treated with two different dosage regimens of miltefosine (Regimen I- 50mg twice daily for 90 days and Regimen II- 50 mg thrice for 60 days) and the clinical outcome assessed monthly." | 1.42 | Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. ( Avishek, K; Deep, DK; Ramesh, V; Salotra, P; Singh, R; Verma, A; Verma, S, 2015) |
| "Miltefosine [hexadecylphosphocholine (HPC)] is the only orally bioavailable drug for the disease visceral leishmaniasis, which is caused by the protozoan parasite Leishmania donovani." | 1.42 | Platelet-activating factor receptor contributes to antileishmanial function of miltefosine. ( de Castro, W; Dey, R; Gangalum, PR; Majumdar, S; Rivas, L; Saha, B; Singh, S; Vieira, LQ, 2015) |
| "Miltefosine was effective in the treatment of Lc-LUC-infected hamsters, as demonstrated by the reduction in parasite burden in a dose-dependent manner and by prolongation of animal survival." | 1.42 | Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging. ( Coelho, AC; Cotrim, PC; Oliveira, JC; Reimão, JQ; Trinconi, CT; Uliana, SR, 2015) |
| "Visceral leishmaniasis is a life-threatening disease that affects nearly a million people every year." | 1.40 | Development of antileishmanial lipid nanocomplexes. ( Abreu, S; Barratt, G; Chaminade, P; Cheron, M; Gueutin, C; Loiseau, PM; Pham, TT, 2014) |
| "To identify epidemiological and clinical risk factors for relapse of VL in patients recently treated with standard dosing of miltefosine in India and Nepal." | 1.40 | Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. ( Boelaert, M; Dorlo, TP; Dujardin, JC; Hasker, E; Ostyn, B; Rijal, S; Sundar, S, 2014) |
| "Achieving a sufficient exposure to miltefosine is a significant and critical factor for VL treatment success, suggesting an urgent need to evaluate the recently proposed optimal allometric miltefosine dosing regimen." | 1.40 | Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. ( Beijnen, JH; Bhattarai, N; Boelaert, M; de Vries, PJ; Dorlo, TP; Dujardin, JC; Huitema, AD; Ostyn, B; Rijal, S; Singh, R; Uranw, S, 2014) |
| "Parasite fingerprints of pretreatment and relapse bone marrow isolates within 8 patients were similar, suggesting that clinical relapses were not due to reinfection with a new strain." | 1.39 | Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. ( Beijnen, JH; Bhattarai, NR; Boelaert, M; Das, ML; Decuypere, S; Dhakal, SS; Dorlo, TP; Dujardin, JC; Karki, P; Ostyn, B; Rai, K; Rijal, S; Singh, R; Uranw, S; Vanaerschot, M, 2013) |
| "Miltefosine was significantly more efficacious than marbofloxacin (P < 0." | 1.38 | Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum. ( Badino, P; Farca, AM; Ferroglio, E; Miniscalco, B; Monticelli, P; Odore, R; Trisciuoglio, A, 2012) |
| " In the present study, we have explored the antileishmanial efficacy of a subcurative dose of miltefosine in combination with free as well as liposomal palmitoyl tuftsin (p-tuftsin) using a Leishmania donovani/BALB/c mouse model." | 1.38 | Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis. ( Gupta, S; Haq, W; Sane, SA; Shakya, N, 2012) |
| " Pharmacokinetic (PK) data for miltefosine in females are lacking; a previously developed population PK model and a comprehensive anthropometric dataset were used to simulate PK data for Indian female VL patients receiving miltefosine for 5, 7, 10 or 28 days." | 1.38 | Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. ( Balasegaram, M; Beijnen, JH; de Vries, PJ; Dorlo, TP; Huitema, AD; Lima, MA, 2012) |
| " However, primaquine exhibits low oral bioavailability due to oxidative deamination of its aliphatic chain." | 1.38 | Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum. ( Gomes, MS; Gomes, P; Matos, J; Moreira, R; Tomás, A; Vale, N; Vale-Costa, S, 2012) |
| " To combat this situation, leishmanicidal efficacy of already marketed standard antifungal drug, fluconazole under the approach of "therapeutic switching" in combination with standard antileishmanial drug, miltefosine, and a potent immunomodulator agent, picroliv, were evaluated in hamsters infected with Leishmania donovani." | 1.37 | Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv. ( Gupta, S; Sane, SA; Shakya, N, 2011) |
| "Combination therapy for the treatment of visceral leishmaniasis has increasingly been advocated as a way to increase treatment efficacy and tolerance, to reduce treatment duration and cost, and to limit the emergence of drug resistance." | 1.37 | Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis. ( Gupta, S; Sane, SA; Shakya, N, 2011) |
| " Furthermore, these compounds distributed to target tissues (liver and spleen) and had a moderate oral bioavailability (up to 25%), a large volume of distribution, and an elimination half-life ranging from 1 to 2 days in mice." | 1.36 | Novel arylimidamides for treatment of visceral leishmaniasis. ( Boykin, DW; Hall, JE; Kyle, DE; Liu, Q; Madhubala, R; Mandal, S; Munde, M; Pandharkar, T; Parman, T; Riccio, E; Srivastava, A; Stephens, CE; Sweat, JM; Tidwell, RR; Wang, MZ; Werbovetz, KA; Wilson, WD; Zhu, X, 2010) |
| "Oral miltefosine was then administered." | 1.36 | Use of miltefosine in the treatment of visceral leishmaniasis in children at a tertiary care hospital of Karachi. ( Humayun, KN; Jehan, F; Khalid, U; Saleem, T; Soofi, S, 2010) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 1.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Visceral leishmaniasis is a systemic parasitic disease that is fatal unless treated." | 1.36 | Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. ( Balasegaram, M; Boelaert, M; Faiz, MA; Meheus, F; Olliaro, P; Rijal, S; Sundar, S, 2010) |
| "Miltefosine was used in relapse treatments (50 mg, b." | 1.35 | Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients. ( Coelho, F; Marques, N; Meliço-Silvestre, A; Oliveira, J; Sá, R; Saraiva Da Cunha, J, 2008) |
| "To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India." | 1.35 | Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. ( Olliaro, P; Sundar, S, 2009) |
| "Miltefosine promotes p38MAP kinase-dependent anti-leishmanial functions and IL-12-dependent Th1 response." | 1.35 | Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. ( Agarwal, R; Kamat, V; Maiti, M; Martin, S; Saha, B; Wadhone, P, 2009) |
| "Without treatment, visceral leishmaniasis is inevitably fatal." | 1.35 | Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. ( Clement, JG; Gershkovich, P; Thornton, SJ; Tidwell, RR; Wasan, EK; Wasan, KM; Werbovetz, KA; Zhu, X, 2009) |
| "We carried out a retrospective and descriptive study of 4 HIV infected patients with relapsing visceral leishmaniasis (VL) seen at 2 tertiary-care hospitals in Spain during the last 6 y, in whom miltefosine was used as a compassionate use treatment at a dosage of 50 mg b." | 1.35 | Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. ( Casquero, A; Fernández-Guerrero, ML; Górgolas, M; Refoyo, E; Troya, J, 2008) |
| "Treatment with amphotericin B deoxycholate was the most effective approach in the baseline analysis and averted 87." | 1.34 | Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. ( Boelaert, M; Diap, G; Gerstl, S; Guerin, PJ; Meheus, F; Van der Stuyft, P; Vanlerberghe, V, 2007) |
| "Wilson disease is an autosomal recessive disorder of copper metabolism in which copper is deposited in the brain and liver." | 1.34 | Wilson disease with visceral leishmaniasis: an extremely uncommon presentation. ( Bhattacharya, SK; Bimal, S; Das, P; Das, VN; Kumar, N; Lal, CS; Pandey, K; Singh, D; Sinha, PK; Topno, RK; Verma, N; Verma, RB, 2007) |
| " We therefore examined the possibility of minimizing these effects by applying miltefosine in lower doses in combination with picrloviv, an immunomodulator against Leishmania donovani in hamsters (Mesocricetus auratus)." | 1.33 | Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis. ( Gupta, S; Ramesh, SC; Srivastava, VM, 2005) |
| "Oral miltefosine appears to be an important alternative for the treatment of PKDL in India and confirmatory studies in controlled clinical trials are needed." | 1.33 | Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. ( Agrawal, D; Agrawal, S; Chakravarty, J; Chhabra, A; Kumar, K; Singh, V; Sundar, S, 2006) |
| "Pentamidine was the first drug to be used and cured 99% of these refractory patients, but over time even with double the amount of initial doses, it cures only 69-78% patients now and its use has largely been abandoned in India." | 1.31 | Drug resistance in Indian visceral leishmaniasis. ( Sundar, S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (2.44) | 18.2507 |
| 2000's | 94 (28.66) | 29.6817 |
| 2010's | 183 (55.79) | 24.3611 |
| 2020's | 43 (13.11) | 2.80 |
| Authors | Studies |
|---|---|
| Castanys-Muñoz, E | 1 |
| Pérez-Victoria, JM | 1 |
| Gamarro, F | 3 |
| Castanys, S | 2 |
| Kumar, D | 6 |
| Kulshrestha, A | 2 |
| Singh, R | 7 |
| Salotra, P | 11 |
| Yang, M | 1 |
| Arai, C | 1 |
| Bakar Md, A | 1 |
| Lu, J | 1 |
| Ge, JF | 1 |
| Pudhom, K | 1 |
| Takasu, K | 1 |
| Kasai, K | 1 |
| Kaiser, M | 3 |
| Brun, R | 2 |
| Yardley, V | 12 |
| Itoh, I | 1 |
| Ihara, M | 1 |
| Wang, MZ | 3 |
| Zhu, X | 5 |
| Srivastava, A | 2 |
| Liu, Q | 1 |
| Sweat, JM | 2 |
| Pandharkar, T | 3 |
| Stephens, CE | 1 |
| Riccio, E | 1 |
| Parman, T | 1 |
| Munde, M | 1 |
| Mandal, S | 1 |
| Madhubala, R | 1 |
| Tidwell, RR | 2 |
| Wilson, WD | 1 |
| Boykin, DW | 3 |
| Hall, JE | 1 |
| Kyle, DE | 2 |
| Werbovetz, KA | 5 |
| Papanastasiou, I | 1 |
| Prousis, KC | 1 |
| Georgikopoulou, K | 1 |
| Pavlidis, T | 1 |
| Scoulica, E | 1 |
| Kolocouris, N | 1 |
| Calogeropoulou, T | 1 |
| Plano, D | 1 |
| Baquedano, Y | 1 |
| Moreno-Mateos, D | 1 |
| Font, M | 1 |
| Jiménez-Ruiz, A | 1 |
| Palop, JA | 1 |
| Sanmartín, C | 1 |
| Reid, CS | 1 |
| Farahat, AA | 2 |
| Tiwari, A | 2 |
| Kumar, S | 2 |
| Suryawanshi, SN | 2 |
| Mittal, M | 2 |
| Vishwakarma, P | 9 |
| Gupta, S | 23 |
| Shivahare, R | 7 |
| Kant, P | 1 |
| Sharma, M | 1 |
| Chauhan, K | 1 |
| Suthar, MK | 1 |
| Sharma, A | 3 |
| Saxena, JK | 1 |
| Lal, J | 2 |
| Chandra, P | 1 |
| Kumar, B | 1 |
| Chauhan, PM | 2 |
| Gopinath, VS | 1 |
| Pinjari, J | 1 |
| Dere, RT | 1 |
| Verma, A | 4 |
| Moger, M | 1 |
| Kumar Goud, PS | 1 |
| Ramanathan, V | 1 |
| Bose, P | 1 |
| Rao, MV | 1 |
| Puri, SK | 2 |
| Launay, D | 5 |
| Martin, D | 2 |
| Korthikunta, V | 1 |
| Tadigoppula, N | 1 |
| Papadopoulou, MV | 1 |
| Bloomer, WD | 1 |
| Rosenzweig, HS | 1 |
| Wilkinson, SR | 1 |
| Naman, CB | 1 |
| Gupta, G | 2 |
| Varikuti, S | 1 |
| Chai, H | 1 |
| Doskotch, RW | 1 |
| Satoskar, AR | 2 |
| Kinghorn, AD | 1 |
| Van Horn, KS | 1 |
| Barber, MM | 1 |
| Yang, S | 2 |
| Manetsch, R | 1 |
| Mowbray, CE | 2 |
| Braillard, S | 5 |
| Speed, W | 1 |
| Glossop, PA | 2 |
| Whitlock, GA | 2 |
| Gibson, KR | 1 |
| Mills, JE | 1 |
| Brown, AD | 1 |
| Gardner, JM | 1 |
| Cao, Y | 1 |
| Hua, W | 1 |
| Morgans, GL | 1 |
| Feijens, PB | 1 |
| Matheeussen, A | 1 |
| Maes, LJ | 1 |
| Bosc, D | 1 |
| Mouray, E | 1 |
| Cojean, S | 2 |
| Franco, CH | 1 |
| Loiseau, PM | 7 |
| Freitas-Junior, LH | 1 |
| Moraes, CB | 1 |
| Grellier, P | 1 |
| Dubois, J | 1 |
| Pandey, S | 1 |
| Chauhan, SS | 1 |
| Jaiswal, S | 1 |
| Thompson, AM | 4 |
| O'Connor, PD | 4 |
| Blaser, A | 2 |
| Maes, L | 20 |
| Franzblau, SG | 4 |
| Wan, B | 4 |
| Wang, Y | 2 |
| Ma, Z | 4 |
| Denny, WA | 4 |
| Mattamana, M | 1 |
| Joice, A | 1 |
| Holt, E | 1 |
| Banerjee, M | 1 |
| Gragg, JL | 1 |
| Hu, L | 1 |
| Kumar, A | 6 |
| Jagu, E | 1 |
| Pomel, S | 1 |
| Diez-Martinez, A | 1 |
| Ramiandrasoa, F | 1 |
| Krauth-Siegel, RL | 1 |
| Pethe, S | 1 |
| Blonski, C | 1 |
| Labruère, R | 1 |
| Marshall, AJ | 3 |
| Chatelain, E | 3 |
| Cooper, CB | 3 |
| Charan Raja, MR | 2 |
| Velappan, AB | 1 |
| Chellappan, D | 1 |
| Debnath, J | 2 |
| Kar Mahapatra, S | 3 |
| Saccoliti, F | 1 |
| Madia, VN | 1 |
| Tudino, V | 1 |
| De Leo, A | 1 |
| Pescatori, L | 1 |
| Messore, A | 1 |
| De Vita, D | 1 |
| Scipione, L | 1 |
| Mäser, P | 1 |
| Calvet, CM | 1 |
| Jennings, GK | 1 |
| Podust, LM | 1 |
| Costi, R | 1 |
| Di Santo, R | 1 |
| Upadhyay, A | 1 |
| Chandrakar, P | 3 |
| Parmar, N | 4 |
| Singh, SK | 3 |
| Rashid, M | 2 |
| Kushwaha, P | 1 |
| Wahajuddin, M | 2 |
| Sashidhara, KV | 1 |
| Kar, S | 4 |
| Gunaganti, N | 1 |
| Mitra, K | 1 |
| Narender, T | 1 |
| Nagle, A | 1 |
| Biggart, A | 1 |
| Be, C | 1 |
| Srinivas, H | 1 |
| Hein, A | 1 |
| Caridha, D | 1 |
| Sciotti, RJ | 1 |
| Pybus, B | 1 |
| Kreishman-Deitrick, M | 1 |
| Bursulaya, B | 1 |
| Lai, YH | 1 |
| Gao, MY | 1 |
| Liang, F | 1 |
| Mathison, CJN | 1 |
| Liu, X | 2 |
| Yeh, V | 1 |
| Smith, J | 1 |
| Lerario, I | 1 |
| Xie, Y | 1 |
| Chianelli, D | 1 |
| Gibney, M | 1 |
| Berman, A | 1 |
| Chen, YL | 1 |
| Jiricek, J | 1 |
| Davis, LC | 1 |
| Ballard, J | 1 |
| Khare, S | 1 |
| Eggimann, FK | 1 |
| Luneau, A | 1 |
| Groessl, T | 1 |
| Shapiro, M | 1 |
| Richmond, W | 1 |
| Johnson, K | 1 |
| Rudewicz, PJ | 1 |
| Rao, SPS | 1 |
| Thompson, C | 1 |
| Tuntland, T | 1 |
| Spraggon, G | 1 |
| Glynne, RJ | 1 |
| Supek, F | 1 |
| Wiesmann, C | 1 |
| Molteni, V | 1 |
| Jacobs, RT | 1 |
| Speake, J | 1 |
| Pandi, B | 1 |
| Nare, B | 1 |
| Freund, Y | 1 |
| Wall, RJ | 1 |
| Carvalho, S | 1 |
| Bello, D | 1 |
| Van den Kerkhof, M | 7 |
| Caljon, G | 12 |
| Gilbert, IH | 1 |
| Corpas-Lopez, V | 1 |
| Lukac, I | 1 |
| Patterson, S | 1 |
| Zuccotto, F | 1 |
| Wyllie, S | 1 |
| McNamara, N | 1 |
| Saunders, E | 1 |
| Varghese, S | 1 |
| Zheng, R | 1 |
| Simpson, K | 1 |
| Varma, DM | 1 |
| Johnson, MM | 2 |
| Hasan Zahid, MS | 1 |
| Bachelder, EM | 2 |
| Ainslie, KM | 2 |
| No, JH | 2 |
| Koh, D | 1 |
| Shum, D | 1 |
| Das, N | 1 |
| Patra, B | 1 |
| Roy, J | 1 |
| Talukdar, A | 1 |
| Ganguly, D | 1 |
| McConville, M | 1 |
| Baell, J | 1 |
| Monge-Maillo, B | 2 |
| Norman, FF | 1 |
| Chamorro-Tojeiro, S | 1 |
| Gioia, F | 1 |
| Pérez-Molina, JA | 1 |
| Chicharro, C | 1 |
| Moreno, J | 2 |
| López-Vélez, R | 4 |
| Sengupta, S | 1 |
| Chatterjee, M | 11 |
| Gonçalves, G | 2 |
| Campos, MP | 2 |
| Gonçalves, AS | 1 |
| Medeiros, LCS | 1 |
| Figueiredo, FB | 2 |
| Burza, S | 6 |
| Mahajan, R | 4 |
| Kazmi, S | 1 |
| Alexander, N | 4 |
| Kumar, V | 1 |
| Lasry, E | 1 |
| Harshana, A | 1 |
| de Lima Pereira, A | 2 |
| Das, P | 21 |
| Verma, N | 12 |
| Das, VNR | 5 |
| Lal, CS | 10 |
| Rewari, B | 1 |
| Goyal, V | 4 |
| Rijal, S | 19 |
| Alves, F | 14 |
| Gill, N | 1 |
| Pandey, K | 22 |
| Carvalho, LM | 1 |
| Gusmão, MR | 1 |
| Costa, AFP | 1 |
| de Brito, RCF | 1 |
| Aguiar-Soares, RDO | 1 |
| Cardoso, JMO | 1 |
| Reis, AB | 1 |
| Carneiro, CM | 1 |
| Roatt, BM | 2 |
| Ayres, EDCBS | 2 |
| Dias, ÁFLR | 2 |
| Monteiro, BRG | 1 |
| Pazzini, SS | 1 |
| Barbosa, MEC | 1 |
| Silva, EBD | 1 |
| Macedo, LFDC | 1 |
| Sousa, VRF | 2 |
| Dutra, V | 1 |
| Nakazato, L | 1 |
| Almeida, ADBPF | 2 |
| Musa, AM | 4 |
| Mbui, J | 4 |
| Mohammed, R | 2 |
| Olobo, J | 6 |
| Ritmeijer, K | 7 |
| Alcoba, G | 1 |
| Muthoni Ouattara, G | 1 |
| Egondi, T | 1 |
| Nakanwagi, P | 1 |
| Omollo, T | 2 |
| Wasunna, M | 8 |
| Verrest, L | 2 |
| Dorlo, TPC | 5 |
| Musa Younis, B | 1 |
| Nour, A | 1 |
| Taha Ahmed Elmukashfi, E | 1 |
| Ismail Omer Haroun, A | 1 |
| Khalil, EAG | 2 |
| Njenga, S | 4 |
| Fikre, H | 2 |
| Mekonnen, T | 1 |
| Mersha, D | 1 |
| Sisay, K | 1 |
| Sagaki, P | 2 |
| Alvar, J | 9 |
| Solomos, A | 4 |
| Melcon-Fernandez, E | 1 |
| Galli, G | 1 |
| García-Estrada, C | 1 |
| Balaña-Fouce, R | 2 |
| Reguera, RM | 2 |
| Pérez-Pertejo, Y | 1 |
| Matralis, DT | 1 |
| Koutinas, AF | 1 |
| Papadogiannaki, IE | 1 |
| Papadopoulos, EG | 1 |
| Papadogiannakis, EI | 1 |
| de Jong, MK | 1 |
| Rappoldt, A | 1 |
| Broere, F | 1 |
| Piek, CJ | 1 |
| Tirado, TC | 1 |
| Negrão, DD | 1 |
| Silva, GMPD | 1 |
| Poleto, APCM | 1 |
| Hartin, TP | 1 |
| Silva, JBA | 1 |
| Castilhos, MMS | 1 |
| Ramos, RAN | 1 |
| Giannelli, A | 1 |
| Fasquelle, F | 1 |
| Scuotto, A | 1 |
| Betbeder, D | 1 |
| Van Bocxlaer, K | 1 |
| Dixon, J | 1 |
| Platteeuw, JJ | 1 |
| Van Den Heuvel, D | 1 |
| Mcarthur, KN | 1 |
| Harris, A | 2 |
| Alavijeh, M | 1 |
| Croft, SL | 12 |
| Hassan, AHE | 1 |
| Bayoumi, WA | 1 |
| El-Sayed, SM | 1 |
| Phan, TN | 1 |
| Kim, YJ | 1 |
| Lee, CH | 1 |
| Cho, SB | 1 |
| Oh, T | 1 |
| Ham, G | 1 |
| Mahmoud, K | 1 |
| Lee, YS | 1 |
| Roseboom, IC | 1 |
| Chu, WY | 1 |
| Huitema, ADR | 1 |
| Mano, C | 1 |
| Kongkaew, A | 1 |
| Tippawangkosol, P | 1 |
| Junkum, A | 1 |
| Siriyasatien, P | 1 |
| Jariyapan, N | 1 |
| Carnielli, JBT | 2 |
| Monti-Rocha, R | 2 |
| Costa, DL | 2 |
| Molina Sesana, A | 1 |
| Pansini, LNN | 1 |
| Segatto, M | 1 |
| Mottram, JC | 2 |
| Costa, CHN | 2 |
| Carvalho, SFG | 2 |
| Dietze, R | 3 |
| Zahid, MSH | 1 |
| Tokarski, RJ | 1 |
| Fuchs, JR | 1 |
| Van Bockstal, L | 6 |
| Sádlová, J | 2 |
| Suau, HA | 1 |
| Hendrickx, S | 15 |
| Meneses, C | 1 |
| Kamhawi, S | 1 |
| Volf, P | 2 |
| Singh, SN | 2 |
| Singh, RS | 2 |
| Strub-Wourgaft, N | 5 |
| Bern, C | 2 |
| Hightower, A | 2 |
| Sunyoto, T | 3 |
| Lima, N | 2 |
| Saurabh, S | 1 |
| Mahabir, M | 1 |
| Ramesh, V | 9 |
| Dixit, KK | 1 |
| Sharma, N | 1 |
| Bulté, D | 5 |
| Mondelaers, A | 7 |
| Aslan, H | 1 |
| Rivas, L | 2 |
| Reimão, JQ | 3 |
| Pita Pedro, DP | 1 |
| Coelho, AC | 2 |
| Topno, RK | 9 |
| Rabi Das, VN | 2 |
| Kumar, M | 1 |
| Madhukar, M | 1 |
| Agrawal, K | 1 |
| Siddiqui, NA | 3 |
| Bimal, S | 5 |
| Ferreira, C | 1 |
| Mesquita, I | 1 |
| Barbosa, AM | 1 |
| Osório, NS | 1 |
| Torrado, E | 1 |
| Beauparlant, CJ | 1 |
| Droit, A | 1 |
| Cunha, C | 1 |
| Carvalho, A | 1 |
| Saha, B | 8 |
| Estaquier, J | 1 |
| Silvestre, R | 1 |
| Camilleri, M | 1 |
| Richards, H | 1 |
| Pomplun, S | 1 |
| Wilson, A | 1 |
| Checkley, A | 1 |
| Rabin, N | 1 |
| Adriaensen, W | 1 |
| Cuypers, B | 2 |
| Cordero, CF | 1 |
| Mengasha, B | 1 |
| Blesson, S | 3 |
| Cnops, L | 2 |
| Kaye, PM | 1 |
| Diro, E | 5 |
| van Griensven, J | 5 |
| Eberhardt, E | 7 |
| Hendrickx, R | 1 |
| Monnerat, S | 1 |
| da Silva, JC | 1 |
| Nunes, JB | 1 |
| Gontijo, VS | 1 |
| Malaquias, LCC | 1 |
| de Freitas, RP | 1 |
| Alves, RB | 1 |
| Colombo, FA | 1 |
| Laurenti, MD | 1 |
| Marques, MJ | 1 |
| de Oliveira Martins, DT | 1 |
| Maruyama, FH | 1 |
| de Oliveira, RG | 1 |
| de Carvalho, MR | 1 |
| Teixeira, ALS | 1 |
| Mendonça, AJ | 1 |
| Parvez, S | 1 |
| Yadagiri, G | 1 |
| Gedda, MR | 1 |
| Singh, A | 5 |
| Singh, OP | 2 |
| Sundar, S | 46 |
| Mudavath, SL | 1 |
| Palić, S | 1 |
| Kip, AE | 5 |
| Beijnen, JH | 9 |
| Musa, A | 2 |
| Jaiteh, MB | 1 |
| İnkaya, AÇ | 1 |
| Üner, A | 1 |
| Elçin, G | 1 |
| Ergüven, S | 1 |
| Kurtulan, O | 1 |
| Harxhi, A | 1 |
| Akova, M | 1 |
| Pai, K | 2 |
| Bhattacharyya, M | 1 |
| Bodhale, NP | 1 |
| Pal, B | 2 |
| Olías-Molero, AI | 2 |
| Fontán-Matilla, E | 1 |
| Cuquerella, M | 1 |
| Alunda, JM | 2 |
| Voak, AA | 1 |
| Coteron-Lopez, JM | 1 |
| Angulo-Barturen, I | 1 |
| Ferrer-Bazaga, S | 1 |
| Seifert, K | 4 |
| Singh-Phulgenda, S | 1 |
| Dahal, P | 1 |
| Ngu, R | 1 |
| Maguire, BJ | 1 |
| Hawryszkiewycz, A | 1 |
| Rashan, S | 1 |
| Brack, M | 1 |
| Halleux, CM | 1 |
| Stepniewska, K | 1 |
| Olliaro, PL | 3 |
| Guerin, PJ | 4 |
| Costa, RR | 1 |
| Oliveira-da-Silva, JA | 1 |
| Reis, TAR | 1 |
| Tavares, GSV | 1 |
| Mendonça, DVC | 1 |
| Freitas, CS | 1 |
| Lage, DP | 1 |
| Martins, VT | 1 |
| Antinarelli, LMR | 1 |
| Machado, AS | 1 |
| Bandeira, RS | 1 |
| Ludolf, F | 1 |
| Santos, TTO | 1 |
| Brito, RCF | 1 |
| Humbert, MV | 1 |
| Menezes-Souza, D | 1 |
| Duarte, MC | 1 |
| Chávez-Fumagalli, MA | 1 |
| Coimbra, ES | 1 |
| Coelho, EAF | 1 |
| Kar, A | 1 |
| Jayaraman, A | 1 |
| Srinivasan, S | 1 |
| Dirkx, L | 1 |
| De Trez, C | 1 |
| Timmermans, JP | 1 |
| Pagliano, P | 1 |
| Esposito, S | 1 |
| Mabille, D | 1 |
| Cos, P | 7 |
| Delputte, P | 7 |
| Tegazzini, D | 2 |
| Cantizani, J | 3 |
| Peña, I | 4 |
| Martín, J | 3 |
| Coterón, JM | 2 |
| Rahman, R | 1 |
| Haque, R | 2 |
| Jamil, K | 1 |
| Faiz, A | 1 |
| Samad, R | 1 |
| Ellis, S | 5 |
| Balasegaram, M | 9 |
| Boer, MD | 1 |
| Sharma, B | 3 |
| Deep, DK | 3 |
| Bhandari, V | 2 |
| Sharma, V | 3 |
| Wajid, S | 1 |
| Dujardin, JC | 15 |
| Kansal, S | 1 |
| Chakravarty, J | 9 |
| Malaviya, P | 2 |
| Boelaert, M | 17 |
| Hasker, E | 5 |
| Ostyn, B | 9 |
| Darcis, G | 1 |
| Van der Auwera, G | 1 |
| Giot, JB | 1 |
| Hayette, MP | 1 |
| Tassin, F | 1 |
| Arrese Estrada, J | 1 |
| Moutschen, M | 1 |
| de Leval, L | 1 |
| Leonard, P | 1 |
| Khanra, S | 1 |
| Sarraf, NR | 1 |
| Das, AK | 1 |
| Roy, S | 5 |
| Manna, M | 1 |
| Younis, BM | 2 |
| Ellis, SJ | 2 |
| Kirigi, G | 4 |
| Hailu, A | 5 |
| Karlsson, MO | 1 |
| Moulik, S | 1 |
| Chaudhuri, SJ | 1 |
| Sardar, B | 1 |
| Ghosh, M | 1 |
| Das, NK | 4 |
| Patel, TA | 1 |
| Scadding, GK | 1 |
| Phillips, DE | 1 |
| Lockwood, DN | 1 |
| Pradhan, A | 1 |
| Basak, S | 1 |
| Chowdhury, T | 1 |
| Mohanta, A | 1 |
| Chatterjee, A | 1 |
| Das, S | 5 |
| Giri, S | 1 |
| Shaha, C | 1 |
| Bhalla, P | 1 |
| Sultana, S | 1 |
| Chiranjivi, AK | 1 |
| Saikia, AK | 1 |
| Dubey, VK | 1 |
| Rodrigo, C | 1 |
| Weeratunga, P | 1 |
| Fernando, SD | 1 |
| Rajapakse, S | 1 |
| Nieto-Meneses, R | 1 |
| Castillo, R | 1 |
| Hernández-Campos, A | 1 |
| Maldonado-Rangel, A | 1 |
| Matius-Ruiz, JB | 1 |
| Trejo-Soto, PJ | 1 |
| Nogueda-Torres, B | 1 |
| Dea-Ayuela, MA | 1 |
| Bolás-Fernández, F | 1 |
| Méndez-Cuesta, C | 1 |
| Yépez-Mulia, L | 1 |
| Ponte-Sucre, A | 1 |
| Barrett, MP | 2 |
| García-Hernández, R | 1 |
| Pountain, AW | 1 |
| Mwenechanya, R | 1 |
| Papadopoulou, B | 1 |
| Tiwary, P | 1 |
| Agarwal, D | 2 |
| Travi, BL | 1 |
| Cordeiro-da-Silva, A | 1 |
| Dantas-Torres, F | 1 |
| Miró, G | 3 |
| Armitage, EG | 1 |
| Alqaisi, AQI | 1 |
| Godzien, J | 1 |
| Mbekeani, AJ | 1 |
| Alonso-Herranz, V | 1 |
| López-Gonzálvez, Á | 1 |
| Gabarro, R | 1 |
| Denny, PW | 1 |
| Barbas, C | 1 |
| Dhorm Pimentel de Moraes, AR | 1 |
| Tavares, GD | 1 |
| Soares Rocha, FJ | 1 |
| de Paula, E | 1 |
| Giorgio, S | 1 |
| Troyano, A | 1 |
| Montoya, A | 2 |
| Fariñas, F | 1 |
| Fermín, ML | 1 |
| Flores, L | 1 |
| Rojo, C | 1 |
| Checa, R | 2 |
| Gálvez, R | 1 |
| Marino, V | 1 |
| Fragío, C | 1 |
| Martínez-Nevado, E | 1 |
| Halder, A | 1 |
| Shukla, D | 1 |
| Roy, P | 1 |
| Mukherjee, A | 1 |
| Abongomera, C | 1 |
| Buyze, J | 1 |
| Stille, K | 1 |
| Ahmed, F | 1 |
| Jiménez-Antón, MD | 1 |
| García-Calvo, E | 1 |
| Gutiérrez, C | 1 |
| Escribano, MD | 1 |
| Kayali, N | 1 |
| Luque-García, JL | 1 |
| Corral, MJ | 1 |
| Costi, MP | 1 |
| Torrado, JJ | 1 |
| Valdivieso, E | 1 |
| Mejías, F | 1 |
| Carrillo, E | 1 |
| Sánchez, C | 1 |
| Hefnawy, A | 1 |
| Manzano, P | 1 |
| De Muylder, G | 1 |
| Hossain, MS | 1 |
| Hossain, AFMA | 1 |
| Mahshin, M | 1 |
| Hossain, MA | 1 |
| Shamsuzzaman, AKM | 1 |
| Maruf, S | 2 |
| Ghosh, P | 2 |
| Ahuja, V | 1 |
| Mondal, D | 6 |
| Omollo, R | 4 |
| Kimutai, R | 3 |
| Were, L | 1 |
| Egondi, TW | 1 |
| Nath, P | 2 |
| Islam, MR | 1 |
| Aktar, F | 1 |
| Anuwarul, A | 1 |
| Basher, A | 2 |
| Crouch, K | 1 |
| Forrester, S | 1 |
| Silva, VC | 1 |
| Damasceno, JD | 1 |
| Brown, E | 1 |
| Dickens, NJ | 1 |
| Jeffares, DC | 1 |
| Bhattacharya, A | 1 |
| Ouellette, M | 1 |
| Edwards, T | 3 |
| Admassu, H | 1 |
| Kibret, A | 1 |
| Bardonneau, C | 1 |
| Zijlstra, EE | 1 |
| Soipei, P | 1 |
| Mutinda, B | 1 |
| Omwalo, G | 1 |
| Tadesse, F | 1 |
| Dos Santos Nogueira, F | 1 |
| Avino, VC | 1 |
| Galvis-Ovallos, F | 1 |
| Pereira-Chioccola, VL | 1 |
| Moreira, MAB | 1 |
| Romariz, APPL | 1 |
| Molla, LM | 1 |
| Menz, I | 1 |
| Pijpers, J | 1 |
| den Boer, ML | 1 |
| Essink, DR | 1 |
| Álvarez-Velilla, R | 1 |
| Gutiérrez-Corbo, MDC | 1 |
| Punzón, C | 1 |
| Pérez-Pertejo, MY | 1 |
| Fresno, M | 1 |
| Daza González, MA | 1 |
| Fragío Arnold, C | 1 |
| Fermín Rodríguez, M | 1 |
| Portero Fuentes, M | 1 |
| Rupérez Noguer, C | 1 |
| Martínez Subiela, S | 1 |
| Cerón, JJ | 1 |
| Villamil-Gómez, WE | 1 |
| Calderón-Gomezcaseres, Á | 1 |
| Rodriguez-Morales, AJ | 1 |
| Rashid, MM | 1 |
| Habibullah, AM | 1 |
| Nath, R | 1 |
| Akter, D | 1 |
| Chowdhury, IH | 1 |
| Azim, A | 1 |
| Faiz, MA | 3 |
| Uranw, S | 5 |
| Rai, K | 2 |
| Bhattarai, NR | 3 |
| Dorlo, TP | 11 |
| Vanaerschot, M | 3 |
| Decuypere, S | 1 |
| Dhakal, SS | 1 |
| Das, ML | 1 |
| Karki, P | 1 |
| Singh, RP | 1 |
| Rabidas, VN | 1 |
| Mandal, A | 1 |
| Maia, C | 1 |
| Nunes, M | 1 |
| Marques, M | 1 |
| Henriques, S | 1 |
| Rolão, N | 1 |
| Campino, L | 1 |
| Salam, MA | 1 |
| Siddiqui, MA | 1 |
| Nabi, SG | 1 |
| Bhaskar, KR | 1 |
| Nabi, E | 1 |
| Mitra, G | 3 |
| Lima, MA | 3 |
| Mishra, J | 1 |
| Singh, S | 2 |
| Prajapati, VK | 3 |
| Sharma, S | 1 |
| Rai, M | 7 |
| Avishek, K | 2 |
| Ali, N | 2 |
| Bhattacharya, P | 2 |
| Berg, M | 1 |
| Mesquita, JT | 1 |
| Tempone, AG | 1 |
| de Vries, PJ | 6 |
| Bhattarai, N | 1 |
| Huitema, AD | 3 |
| Rani, M | 1 |
| Rabidas, V | 1 |
| Sahoo, GC | 2 |
| Yadav, PK | 2 |
| Haq, W | 4 |
| Srivastava, M | 1 |
| Carnielli, JB | 1 |
| de Andrade, HM | 1 |
| Pires, SF | 1 |
| Chapeaurouge, AD | 1 |
| Perales, J | 1 |
| Carvalho, SF | 1 |
| Ribeiro, LP | 1 |
| Figueiredo, SG | 1 |
| Lemos, EM | 1 |
| Patole, S | 1 |
| Varghese, GM | 1 |
| Pham, TT | 1 |
| Gueutin, C | 1 |
| Cheron, M | 1 |
| Abreu, S | 2 |
| Chaminade, P | 2 |
| Barratt, G | 1 |
| Lynen, L | 2 |
| Singh, N | 5 |
| Oliveira, JC | 1 |
| Trinconi, CT | 1 |
| Cotrim, PC | 1 |
| Uliana, SR | 1 |
| Lachaud, L | 2 |
| Vakil, NH | 1 |
| Fujinami, N | 1 |
| Shah, PJ | 1 |
| Gangalum, PR | 1 |
| de Castro, W | 1 |
| Vieira, LQ | 1 |
| Dey, R | 1 |
| Majumdar, S | 2 |
| Ali, W | 1 |
| Natu, SM | 1 |
| Isaakidis, P | 1 |
| Sagili, KD | 1 |
| Van Geertruyden, JP | 1 |
| Kevric, I | 1 |
| Cappel, MA | 1 |
| Keeling, JH | 1 |
| Ghosh, S | 3 |
| Mukherjee, S | 2 |
| Mukhopadhyay, D | 4 |
| Barbhuiya, JN | 2 |
| Hazra, A | 1 |
| Ganguly, S | 2 |
| Saha, P | 2 |
| Ghosh, TK | 1 |
| Guha, SK | 1 |
| Kundu, PK | 1 |
| Bera, DK | 1 |
| Basu, N | 1 |
| Maji, AK | 1 |
| Verma, S | 3 |
| Kumar, R | 3 |
| Ansari, MY | 1 |
| Rana, S | 1 |
| Shaw, CD | 1 |
| Lonchamp, J | 1 |
| Downing, T | 1 |
| Imamura, H | 1 |
| Freeman, TM | 1 |
| Cotton, JA | 1 |
| Sanders, M | 1 |
| Blackburn, G | 1 |
| Khanal, B | 1 |
| Illingworth, CJ | 1 |
| Coombs, GH | 1 |
| Carter, KC | 2 |
| Rosing, H | 1 |
| Hillebrand, MJ | 1 |
| Mengesha, B | 1 |
| Schellens, JH | 1 |
| Bhattacharya, SK | 8 |
| Dash, AP | 2 |
| Díaz, R | 1 |
| Aguilar, F | 1 |
| Presa, JL | 1 |
| Martin, JJ | 1 |
| Beyers, J | 1 |
| Costa, S | 1 |
| Machado, M | 1 |
| Cavadas, C | 1 |
| do Céu Sousa, M | 1 |
| Faucher, JF | 1 |
| Morquin, D | 1 |
| Reynes, J | 1 |
| Chirouze, C | 1 |
| Hoen, B | 1 |
| Le Moing, V | 1 |
| Musa, B | 1 |
| Ali, MH | 1 |
| Elamin, MY | 1 |
| Juma, R | 1 |
| Schoone, GJ | 2 |
| Wells, S | 1 |
| Khalil, EA | 2 |
| Strub Wourgaft, N | 1 |
| Ravidas, V | 2 |
| Sinha, SK | 1 |
| Verma, RB | 6 |
| Singh, TP | 1 |
| Dhariwal, AC | 1 |
| Das Gupta, RK | 1 |
| Hasnain, G | 1 |
| Shomik, MS | 1 |
| Rashid, MO | 1 |
| Hossain, S | 1 |
| Hamano, S | 1 |
| Tangalidi, MK | 1 |
| Oikonomidis, IL | 1 |
| Psalla, D | 1 |
| Papadimitriou, S | 1 |
| Kritsepi-Konstantinou, M | 1 |
| Mylonakis, ME | 1 |
| Pérez-Jacoiste Asín, MA | 1 |
| Carrasco-Antón, N | 1 |
| Fernández-Ruiz, M | 1 |
| San Juan, R | 1 |
| Alonso-Moralejo, R | 1 |
| González, E | 1 |
| Andrés, A | 1 |
| López-Medrano, F | 1 |
| Aguado, JM | 1 |
| Murti, K | 1 |
| Ali, V | 1 |
| Siddiqi, NA | 1 |
| Tiwari, B | 1 |
| Pahuja, R | 1 |
| Kumar, P | 2 |
| Rath, SK | 1 |
| Gupta, KC | 1 |
| Goyal, N | 1 |
| Palumbo, E | 2 |
| Marques, N | 1 |
| Sá, R | 1 |
| Coelho, F | 1 |
| Oliveira, J | 1 |
| Saraiva Da Cunha, J | 1 |
| Meliço-Silvestre, A | 1 |
| Ansari, NA | 2 |
| Berman, JJ | 1 |
| Agrawal, N | 1 |
| Vaillant, M | 2 |
| Olliaro, P | 6 |
| Murray, HW | 10 |
| Alborzi, A | 1 |
| Pouladfar, GR | 1 |
| Fakhar, M | 1 |
| Motazedian, MH | 1 |
| Hatam, GR | 1 |
| Kadivar, MR | 1 |
| Manna, L | 3 |
| Vitale, F | 2 |
| Reale, S | 2 |
| Picillo, E | 3 |
| Neglia, G | 1 |
| Vescio, F | 1 |
| Gravino, AE | 3 |
| Guffanti, M | 1 |
| Gaiera, G | 1 |
| Bossolasco, S | 1 |
| Ceserani, N | 1 |
| Ratti, D | 1 |
| Cinque, P | 1 |
| Salmaso, F | 1 |
| Gianotti, N | 1 |
| Lazzarin, A | 1 |
| Decaro, N | 1 |
| Buonavoglia, C | 1 |
| Das, VN | 5 |
| Singh, D | 2 |
| Thakur, CP | 7 |
| Meenakshi Thakur, AK | 1 |
| Thakur, S | 2 |
| Woerly, V | 1 |
| Maynard, L | 1 |
| Sanquer, A | 1 |
| Eun, HM | 1 |
| Pandey, BD | 1 |
| Kaneko, O | 1 |
| Yanagi, T | 1 |
| Hirayama, K | 1 |
| Wadhone, P | 1 |
| Maiti, M | 1 |
| Agarwal, R | 1 |
| Kamat, V | 1 |
| Martin, S | 1 |
| Wasan, KM | 1 |
| Wasan, EK | 1 |
| Gershkovich, P | 1 |
| Clement, JG | 1 |
| Thornton, SJ | 1 |
| Darley, S | 1 |
| Laxminarayan, R | 1 |
| Collini, P | 1 |
| Premchand, N | 1 |
| Lockwood, D | 1 |
| Greig, J | 1 |
| Ramam, M | 1 |
| Meheus, F | 3 |
| Sane, SA | 8 |
| Shakya, N | 8 |
| Humayun, KN | 1 |
| Saleem, T | 1 |
| Khalid, U | 1 |
| Jehan, F | 1 |
| Soofi, S | 1 |
| Khandpur, S | 1 |
| Chaturvedi, P | 1 |
| Kumar, U | 1 |
| Khaitan, BK | 1 |
| Samantaray, JC | 1 |
| Sharma, VK | 1 |
| Barragán, P | 1 |
| Olmo, M | 1 |
| Podzamczer, D | 1 |
| Mondal, S | 1 |
| Sinha, PK | 8 |
| Verma, DK | 2 |
| Kumar, N | 7 |
| Alam, S | 2 |
| Kumari, P | 2 |
| Berman, J | 7 |
| Ghalib, H | 2 |
| Arana, B | 4 |
| Sarkar, A | 3 |
| Mandal, G | 1 |
| Goswami, RP | 1 |
| Kshirsagar, N | 1 |
| Ferner, R | 1 |
| Figueroa, BA | 1 |
| Lazdin, J | 1 |
| Nawin, K | 1 |
| Arora, R | 1 |
| Modabber, F | 1 |
| Matlashewski, G | 1 |
| Kroeger, A | 1 |
| Battacharya, S | 1 |
| Zilberstein, D | 1 |
| Katara, GK | 1 |
| Andrade, HM | 1 |
| Toledo, VP | 1 |
| Pinheiro, MB | 1 |
| Guimarães, TM | 1 |
| Oliveira, NC | 1 |
| Castro, JA | 1 |
| Silva, RN | 1 |
| Amorim, AC | 1 |
| Brandão, RM | 1 |
| Yoko, M | 1 |
| Silva, AS | 1 |
| Dumont, K | 1 |
| Ribeiro, ML | 1 |
| Bartchewsky, W | 1 |
| Monte, SJ | 1 |
| Bajpai, P | 1 |
| Abuzaid, AA | 1 |
| Njoroge, N | 1 |
| Kinoti, D | 1 |
| Rahman, M | 1 |
| Ahmed, BN | 1 |
| Chowdhury, MZ | 1 |
| Islam, QT | 1 |
| Sayeedur, R | 1 |
| Rahman, MR | 1 |
| Hossain, M | 1 |
| Bangali, AM | 1 |
| Ahmad, Z | 1 |
| Islam, MN | 1 |
| Mascie-Taylor, CG | 1 |
| Ranjan, A | 2 |
| Michel, G | 1 |
| Ferrua, B | 2 |
| Lang, T | 1 |
| Maddugoda, MP | 1 |
| Munro, P | 1 |
| Pomares, C | 1 |
| Lemichez, E | 1 |
| Marty, P | 3 |
| Kundu, S | 1 |
| Shankar, S | 1 |
| Imbert, L | 1 |
| Ramos, RG | 1 |
| Libong, D | 1 |
| Campos Vieira, N | 1 |
| Vacus, J | 1 |
| Fournet, A | 1 |
| Baudouin, R | 1 |
| Bories, C | 2 |
| Séon-Méniel, B | 1 |
| Figadère, B | 1 |
| Gupta, R | 1 |
| Kushawaha, PK | 1 |
| Samant, M | 1 |
| Jaiswal, AK | 1 |
| Baharia, RK | 1 |
| Dube, A | 4 |
| Farca, AM | 1 |
| Miniscalco, B | 1 |
| Badino, P | 1 |
| Odore, R | 1 |
| Monticelli, P | 1 |
| Trisciuoglio, A | 1 |
| Ferroglio, E | 1 |
| Mukherjee, AK | 1 |
| Adhikari, A | 1 |
| Majumder, S | 1 |
| Bhattacharyya Majumdar, S | 1 |
| Pakrashi, S | 1 |
| Roy, D | 1 |
| Sen, S | 1 |
| Houzé, S | 1 |
| Haouchine, D | 1 |
| Huteau, F | 1 |
| Lariven, S | 1 |
| Hubert, V | 1 |
| Michard, F | 1 |
| Pratlong, F | 1 |
| Le Bras, J | 1 |
| Matheron, S | 1 |
| Bøhler, E | 1 |
| Vase, MØ | 1 |
| Hellberg, YK | 1 |
| Larsen, CS | 1 |
| Petersen, E | 1 |
| Schaumburg, H | 1 |
| Bendix, K | 1 |
| Ravel, C | 1 |
| Bastien, P | 1 |
| Christensen, M | 1 |
| d'Amore, F | 1 |
| Singh, AK | 1 |
| Stark, O | 1 |
| Schonian, G | 1 |
| Eggelte, TA | 2 |
| Azizan, A | 1 |
| Vesely, B | 1 |
| Vale-Costa, S | 1 |
| Vale, N | 1 |
| Matos, J | 1 |
| Tomás, A | 1 |
| Moreira, R | 1 |
| Gomes, P | 1 |
| Gomes, MS | 1 |
| Picado, A | 1 |
| Sinha, P | 1 |
| Jha, TK | 8 |
| Narain, MK | 1 |
| Dujardin, B | 1 |
| Pun, SB | 1 |
| Shah, R | 1 |
| Rosenthal, E | 2 |
| Paterson, R | 1 |
| Desjeux, P | 1 |
| Wasunna, MK | 1 |
| Bryceson, AD | 3 |
| Tripathi, K | 1 |
| Pandey, HP | 1 |
| Jacobs, S | 1 |
| Engel, J | 6 |
| Sindermann, H | 6 |
| Fischer, C | 4 |
| Junge, K | 3 |
| Bryceson, A | 1 |
| Ridley, RG | 1 |
| Agarwal, PK | 1 |
| Roca, B | 1 |
| Spickett, C | 1 |
| Pereira, OC | 1 |
| Mullen, AB | 1 |
| Bachmann, P | 3 |
| Thakur, BB | 1 |
| Sangraula, H | 1 |
| Sharma, KK | 1 |
| Dwivedi, S | 1 |
| Koirala, S | 2 |
| Karbwang, J | 3 |
| Berman, JD | 1 |
| Minodier, P | 3 |
| Robert, S | 1 |
| Retornaz, K | 2 |
| Garnier, JM | 3 |
| Prasad, R | 3 |
| Jaiswal, BP | 2 |
| Singh, UK | 3 |
| Verma, NK | 1 |
| Dey, CS | 1 |
| Bommer, W | 1 |
| Eibl, HJ | 1 |
| Engel, KR | 1 |
| Kuhlencord, A | 2 |
| Zappel, H | 1 |
| Mishra, PK | 1 |
| Kapil, A | 1 |
| Arya, KR | 1 |
| Maurya, R | 1 |
| Dutta, A | 1 |
| Bandyopadhyay, S | 2 |
| Mandal, C | 1 |
| Ramesh, SC | 1 |
| Srivastava, VM | 1 |
| Rakotomanga, M | 1 |
| Saint-Pierre-Chazalet, M | 1 |
| De Doncker, S | 1 |
| Miranda, C | 1 |
| Llanos-Cuentas, A | 1 |
| Chappuis, F | 1 |
| Rihl, M | 1 |
| Stoll, M | 1 |
| Ulbricht, K | 1 |
| Bange, FC | 1 |
| Schmidt, RE | 1 |
| Kumar, K | 1 |
| Agrawal, D | 1 |
| Agrawal, S | 1 |
| Chhabra, A | 1 |
| Singh, V | 1 |
| Belay, AD | 1 |
| Asafa, Y | 1 |
| Mesure, J | 2 |
| Davidson, RN | 2 |
| van der Meide, WF | 1 |
| Godfried, MH | 1 |
| Schallig, HD | 1 |
| Dinant, HJ | 1 |
| Faber, WR | 1 |
| Sur, D | 1 |
| Dejenie, A | 1 |
| Assefa, Y | 1 |
| Hundie, TB | 1 |
| Boots, G | 1 |
| den Boer, M | 1 |
| Mishra, OP | 1 |
| Jayswal, BP | 1 |
| Vanlerberghe, V | 1 |
| Diap, G | 1 |
| Gerstl, S | 1 |
| Van der Stuyft, P | 1 |
| Noël, G | 1 |
| Blanc, P | 1 |
| Uters, M | 1 |
| Wysluch, A | 1 |
| Sommerer, F | 1 |
| Ramadan, H | 1 |
| Loeffelbein, D | 1 |
| Wolff, KD | 1 |
| Hölzle, F | 1 |
| Das, VR | 1 |
| Lal, C | 1 |
| Singh, VP | 1 |
| Anders, G | 1 |
| Ganguly, NK | 1 |
| Pérez-Victoria, FJ | 1 |
| Stettler, M | 1 |
| Sánchez-Cañete, MP | 1 |
| Troya, J | 1 |
| Casquero, A | 1 |
| Refoyo, E | 1 |
| Fernández-Guerrero, ML | 1 |
| Górgolas, M | 1 |
| Antinori, S | 1 |
| Longhi, E | 1 |
| Bestetti, G | 1 |
| Piolini, R | 1 |
| Acquaviva, V | 1 |
| Foschi, A | 1 |
| Trovati, S | 1 |
| Parravicini, C | 1 |
| Corbellino, M | 1 |
| Meroni, L | 1 |
| Thakur, M | 1 |
| Jain, RK | 1 |
| Choudhury, K | 1 |
| Zander, D | 1 |
| Kube, M | 1 |
| Reinhardt, R | 1 |
| Clos, J | 1 |
| Neub, A | 1 |
| Krahl, D | 1 |
| Stich, A | 1 |
| Amon, U | 1 |
| Snowdon, D | 1 |
| Le Fichoux, Y | 1 |
| Rousseau, D | 1 |
| Ruette, S | 1 |
| Lelièvre, A | 1 |
| Grousson, D | 1 |
| Kubar, J | 1 |
| Rosenkaimer, F | 2 |
| Makharia, MK | 2 |
| Goyal, AK | 1 |
| Mandal, AK | 1 |
| Voss, A | 5 |
| Hilgard, P | 1 |
| Nicaise, C | 1 |
| Gire, C | 1 |
| Herwaldt, BL | 1 |
| Delph-Etienne, S | 1 |
| Gupta, LB | 1 |
| Singh, MK | 1 |
| Eibl, H | 2 |
| Sherwood, JA | 1 |
| Makharia, A | 1 |
| More, DK | 1 |
| Agrawal, G | 1 |
| Murray , HW | 1 |
| Escobar, P | 1 |
| Kaminsky, R | 1 |
| Maniera, T | 1 |
| Unger, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa[NCT03129646] | Phase 3 | 439 participants (Actual) | Interventional | 2018-01-24 | Completed | ||
| A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh[NCT01122771] | Phase 3 | 602 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| An Open-label Clinical Trial to Assess the Pharmacokinetics and Safety of Miltefosine Allometric Dose for the Treatment of Children With Primary Visceral Leishmaniasis in Eastern Africa[NCT02431143] | Phase 2 | 30 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine.[NCT02011958] | Phase 3 | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase II Randomized, Parallel Arm, Open-labeled Clinical Trial to Assess the Safety and Efficacy of the Combination of Sodium Stibogluconate Plus Single Dose AmBisome®, Miltefosine Plus Single Dose AmBisome® and Miltefosine Alone for the Treatment of Pr[NCT01067443] | Phase 2 | 151 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500] | Phase 4 | 60 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Combination Chemotherapy for the Treatment of Indian Visceral Leishmaniasis: Miltefosine Plus Liposomal Amphotericin B - Dose and Duration Ranging Study[NCT00370825] | Phase 2 | 200 participants | Interventional | 2006-09-30 | Completed | ||
| The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India[NCT00371995] | Phase 2 | 150 participants (Anticipated) | Interventional | 2007-10-31 | Completed | ||
| Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (t[NCT00696969] | Phase 3 | 634 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Evaluation of the Safety and Clinical Activity of Curaleish Lotion and Cream in the Topical Treatment of Cutaneous Leishmaniasis in Colombia[NCT04072874] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2021-01-31 | Withdrawn (stopped due to Tthe study is in the approval phase by local regulatory authorities) | ||
| Randomized Clinical Trial to Evaluate the Safety and Therapeutic Response of Two ARNICA TINCTURE Treatment Regimes in the Topical Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia[NCT05094908] | Phase 1 | 16 participants (Anticipated) | Interventional | 2023-05-03 | Recruiting | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
45 reviews available for miltefosine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Topics: Animals; Antiprotozoal Agents; Drug Development; Drug Discovery; Humans; Leishmania donovani; Leishm | 2020 |
Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Deoxycholic Acid; Drug Combinations; Humans; Leishma | 2021 |
Visceral leishmaniosis in immunocompromised host: an update and literature review.
Topics: Amphotericin B; HIV Infections; Humans; Immunocompromised Host; Leishmaniasis, Visceral; Phosphorylc | 2017 |
Keratitis After Post-Kala-Azar Dermal Leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Corneal Stroma; Eye Infections, Parasitic; Glucoc | 2018 |
Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.
Topics: Amphotericin B; Antiprotozoal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; | 2018 |
Chemotherapeutics of visceral leishmaniasis: present and future developments.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Drug Resistance, Multiple; | 2018 |
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Drug Therapy, Combination; Humans; Leishmania | 2017 |
Visceral Leishmaniasis-Optimum Treatment Options in Children.
Topics: Amphotericin B; Antiprotozoal Agents; Child; Drug Therapy, Combination; Humans; Leishmaniasis, Visce | 2018 |
Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Reservoirs; Dog Diseases; Dogs; Leishmania infan | 2018 |
The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
Topics: Antiprotozoal Agents; Asia; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcho | 2019 |
Visceral Leishmaniasis and HIV coinfection in East Africa.
Topics: Africa, Eastern; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; Coinfection; HIV Infe | 2014 |
Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Topics: Administration, Oral; Africa, Eastern; Antiprotozoal Agents; Bangladesh; Coinfection; Drug Therapy, | 2015 |
Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasi | 2015 |
New World and Old World Leishmania Infections: A Practical Review.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Deoxycholic Acid; Drug Combinations | 2015 |
Elimination of visceral leishmaniasis on the Indian subcontinent.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Health Services Accessibility; Humans; India; Insect | 2016 |
Evaluating drug resistance in visceral leishmaniasis: the challenges.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance, Multiple; Humans; Leishmania donovan | 2018 |
Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
Topics: Animals; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2008 |
Treatment of leishmaniasis with miltefosine: 2008 status.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Female; Humans; | 2008 |
Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug | 2009 |
Combination therapy for visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Asia; Brazil; Cost-Benefit Analysis; Drug Therapy, Combination | 2010 |
Current diagnosis and treatment of visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antigens, Protozoan; Antiprotozoal Agents; Drug Therapy, Combination; Enzym | 2010 |
Drug combinations for visceral leishmaniasis.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cost-Benefit Analysis; Drug Resista | 2010 |
Visceral leishmaniasis in children: a review.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Child; Drug Resistance; Drug Therapy, Combination; Gl | 2010 |
Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis.
Topics: Adverse Drug Reaction Reporting Systems; Antiprotozoal Agents; Clinical Trials as Topic; Female; Hum | 2011 |
Visceral leishmaniasis: elimination with existing interventions.
Topics: Amphotericin B; Antiprotozoal Agents; Communicable Disease Control; Drug Therapy, Combination; Human | 2011 |
Leishmaniasis: an update of current pharmacotherapy.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Therapy, Combination; Humans; | 2013 |
Treatment of visceral leishmaniasis: a review of current treatment practices.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Developing Countries; HIV Infections; Humans; Leishma | 2002 |
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Asia, Western; Brazil; Developing Countries; Dogs; F | 2002 |
Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Topics: Administration, Oral; Aminoquinolines; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Dose | 2003 |
[Visceral leishmaniasis: new drugs].
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visce | 2003 |
Miltefosine: an oral drug for visceral leishmaniasis.
Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2004 |
Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Com | 2004 |
[Visceral leishmaniases].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antimony; Antiprotozoal Agent | 2004 |
Miltefosine to treat leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis | 2005 |
Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Humans; India; L | 2006 |
Childhood visceral leishmaniasis.
Topics: Administration, Oral; Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Huma | 2006 |
Drug unresponsiveness & combination therapy for kala-azar.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance; Humans; India; Leishmania; Leishmani | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish | 2006 |
Current scenario of drug development for leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish | 2006 |
Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Drug Design; Glycerylphosphorylcholine; Leishm | 2006 |
[Miltefosine: a new remedy for leishmaniasis].
Topics: Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphoryl | 2006 |
[Treatment of visceral leishmaniasis in children].
Topics: Amphotericin B; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Humans; Leishmania | 2007 |
[The leishmaniasis - a parasitel infection as differential diagnosis of malignant tumours of oral mucosa. A case report and review of literature].
Topics: Animals; Combined Modality Therapy; Diagnosis, Differential; Hepatitis C, Chronic; Histiocytes; Huma | 2007 |
Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Americas; Antiprotozoal Agents; Antiretroviral Therapy, Highly A | 2007 |
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
Topics: Adult; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Child; Humans; Leishmania donovani; | 2000 |
Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Child, Preschool; Clinical Trials as Topic | 2001 |
37 trials available for miltefosine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Amphotericin B; Antibodies, Protozoan; Biomarkers; Drug Monitoring; Female; Human | 2021 |
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; HIV | 2022 |
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Topics: Adult; Africa, Eastern; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Drug Therapy, Combin | 2023 |
Intracellular IFN-γ and IL-4 levels of CD4 + and CD8 + T cells in the peripheral blood of naturally infected (Leishmania infantum) symptomatic dogs before and following a 4-week treatment with miltefosine and allopurinol: a double-blinded, controlled and
Topics: Allopurinol; Animals; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Dog Diseases; Dogs; Inter | 2023 |
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Child; Humans; Kenya; Leishmaniasis, Visceral; Paromomycin; Phosphorylc | 2023 |
Natural Resistance of
Topics: Adolescent; Adult; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Female; Humans; Immunity, | 2019 |
Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Endoribonucleases; Female; Gene Expression | 2020 |
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Bangladesh; Child; Child, Preschool; Drug T | 2017 |
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
Topics: Adolescent; Adult; Africa, Eastern; Antiprotozoal Agents; Biological Availability; Child; Female; Hu | 2017 |
Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
Topics: Africa, Eastern; Antiprotozoal Agents; Area Under Curve; Child; Child, Preschool; Drug Administratio | 2019 |
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antiprotozoal Agents; Child; Child, Pres | 2018 |
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
Topics: Adult; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; Coinfection; Drug Therapy, Comb | 2019 |
TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Cells, Cultured; Dendritic Cells; Drug Combinations; Female; HEK293 Cel | 2014 |
Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes.
Topics: Antiprotozoal Agents; Brazil; Drug Resistance; Female; Humans; Leishmania infantum; Leishmaniasis, V | 2014 |
Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosp | 2015 |
Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Drug Administration Schedule; Female; Humans; Leishm | 2015 |
Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
Topics: Antiprotozoal Agents; Calibration; Chromatography, Liquid; Coinfection; Dried Blood Spot Testing; Dr | 2016 |
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
Topics: Adolescent; Adult; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Drug Ther | 2016 |
Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combi | 2017 |
New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Topics: Adult; Amphotericin B; Drug Therapy, Combination; Female; Humans; India; Leishmaniasis, Visceral; Ma | 2008 |
Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Leishmaniasis, Visc | 2009 |
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Creatinine; Dose-R | 2011 |
Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Amphotericin B; Antimony Sodium Gluconate; Child; Drug Therapy, Combination; Huma | 2011 |
Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh.
Topics: Adolescent; Adult; Antiprotozoal Agents; Bangladesh; Child; Child, Preschool; Female; Humans; Leishm | 2011 |
Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Cohort Studies; Female; | 2012 |
Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Administration Schedule; Fema | 2012 |
Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.
Topics: Administration, Oral; Adolescent; Adult; Female; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous | 2013 |
Oral miltefosine for Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Amphotericin B; Animals; Antiprotozoal Agents; Female; Huma | 2002 |
Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Biological Availability; Child; Child, Preschool; Dose-R | 2003 |
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
Topics: Animals; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmaniasis, Visceral; Mal | 2004 |
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Topics: Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Comorbidity; Ethiopia; HIV Infections; Human | 2006 |
Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cross-Sectional Studies; Drug Resis | 2006 |
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiprotozoal Agents; Aspartate | 2007 |
Trial of oral miltefosine for visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Drug Administration Schedule; Humans; | 1998 |
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Aspartate Aminotransferases; Female; | 1999 |
Oral treatment of visceral leishmaniasis with miltefosine.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Female; Humans; Kidney; Leishmaniasis | 1999 |
Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Diarrhea; Drug Administration Schedule; Female; H | 2000 |
246 other studies available for miltefosine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Base Sequence; Bi | 2008 |
In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; DNA Primers; Drug Resistan | 2009 |
Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).
Topics: Animals; Antiprotozoal Agents; Benzothiazoles; Cell Line; Cell Survival; Female; Leishmania donovani | 2010 |
Novel arylimidamides for treatment of visceral leishmaniasis.
Topics: Amidines; Animals; Antiprotozoal Agents; Biological Availability; Cricetinae; Disease Models, Animal | 2010 |
Design and synthesis of new adamantyl-substituted antileishmanial ether phospholipids.
Topics: Antiprotozoal Agents; Cell Line; Cell Survival; Humans; Leishmania infantum; Leishmaniasis, Visceral | 2010 |
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
Topics: Aminophenols; Animals; Antiprotozoal Agents; Cell Line, Tumor; Cyanates; Humans; Inhibitory Concentr | 2011 |
Antileishmanial bis-arylimidamides: DB766 analogs modified in the linker region and bis-arylimidamide structure-activity relationships.
Topics: Amidines; Animals; Antiprotozoal Agents; Furans; Leishmania; Leishmaniasis, Visceral; Macrophages; M | 2012 |
Chemotherapy of leishmaniasis part X: synthesis and bioevaluation of novel terpenyl heterocycles.
Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Cell Survival; Chalcones; Cricetinae; Disease Model | 2013 |
Chemotherapy of leishmaniasis. Part XII: design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents.
Topics: Animals; Antiparasitic Agents; Chlorocebus aethiops; Dose-Response Relationship, Drug; Drug Design; | 2013 |
Discovery of a new class of natural product-inspired quinazolinone hybrid as potent antileishmanial agents.
Topics: Animals; Antiparasitic Agents; Biological Products; Cattle; Cell Line; Chlorocebus aethiops; Criceti | 2013 |
Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cricetinae; Disease Models, Animal; Drug Design; Leishmani | 2013 |
Synthesis and biological evaluation of chalcones as potential antileishmanial agents.
Topics: Animals; Cell Line; Chalcones; Chlorocebus aethiops; Cricetinae; Disease Models, Animal; Dose-Respon | 2014 |
Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
Topics: Amides; Apoptosis; Blood Platelets; Cells, Cultured; Chagas Disease; Flow Cytometry; Heterocyclic Co | 2014 |
Northalrugosidine is a bisbenzyltetrahydroisoquinoline alkaloid from Thalictrum alpinum with in vivo antileishmanial activity.
Topics: Alkaloids; Animals; Disease Models, Animal; Humans; Isoquinolines; Leishmania donovani; Leishmaniasi | 2015 |
SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.
Topics: Animals; Antiprotozoal Agents; Diamines; Humans; Leishmania donovani; Leishmaniasis, Visceral; Mice; | 2015 |
Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity.
Topics: Animals; Antiparasitic Agents; Cricetinae; Female; Humans; Leishmania donovani; Leishmania infantum; | 2015 |
Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antiparasitic Agents; Cell Line; Enzyme Inhibitors; Humans; Im | 2016 |
Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes.
Topics: Amides; Animals; Antiprotozoal Agents; Cell Line; Chlorocebus aethiops; Cricetinae; Humans; Indoles; | 2016 |
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Antitubercular Agents; Cricetinae; Drug Repositioning; Female; High-T | 2016 |
Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chemistry Techniques, Synthetic; Drug Evaluatio | 2016 |
Synthesis and in vitro antikinetoplastid activity of polyamine-hydroxybenzotriazole conjugates.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; NADH, NADPH Oxi | 2017 |
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Antitubercular Agents; Cricetinae; Drug Discovery; Female; Humans; Le | 2017 |
Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cell Survival; Dose-Response Relationship, Drug; Eugenol; Immunomodul | 2017 |
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
Topics: Animals; Antiparasitic Agents; Cell Membrane Permeability; Chagas Disease; Cricetinae; Cytochrome P- | 2018 |
Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Chagas Disease; Female; Humans; Imidazoles; Inhibitory Con | 2018 |
Synthesis, Biological Evaluation, Structure-Activity Relationship, and Mechanism of Action Studies of Quinoline-Metronidazole Derivatives Against Experimental Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Chemistry Techniques, Synthetic; Chlorocebus aethiops; Disease Models | 2019 |
β-Amino acid derivatives as mitochondrial complex III inhibitors of L. donovani: A promising chemotype targeting visceral leishmaniasis.
Topics: Amino Acids; Animals; Antiprotozoal Agents; Cell Survival; Chlorocebus aethiops; Cricetinae; Dose-Re | 2019 |
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
Topics: Animals; Antiprotozoal Agents; Dogs; Humans; Leishmania donovani; Leishmania major; Leishmaniasis, V | 2020 |
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; | 2021 |
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Benzoxazoles; Boron Compounds; Cricetinae; Disease Models, Animal; Do | 2021 |
Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani.
Topics: Antiprotozoal Agents; Humans; Imidazoles; Leishmania donovani; Leishmaniasis, Visceral; Trypanosoma | 2022 |
Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
Topics: Antiprotozoal Agents; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Cutaneous; Leishma | 2022 |
Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Resistance; Fem | 2021 |
Immunochemotherapy for visceral leishmaniasis: combinatorial action of Miltefosine plus LBSapMPL vaccine improves adaptative Th1 immune response with control of splenic parasitism in experimental hamster model.
Topics: Animals; Antigens, Protozoan; Cricetinae; Dogs; Immunity; Leishmania infantum; Leishmaniasis Vaccine | 2022 |
Clinical and parasitological impact of short-term treatment using miltefosine and allopurinol monotherapy or combination therapy in canine visceral leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis, | 2022 |
Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of
Topics: Animals; Antiprotozoal Agents; Female; Leishmania donovani; Leishmaniasis, Visceral; Mice; Nifuratel | 2023 |
Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy.
Topics: Allopurinol; Animals; Creatinine; Dog Diseases; Dogs; Humans; Leishmania infantum; Leishmaniasis; Le | 2023 |
A case of canine visceral leishmaniasis of unknown origin in Curitiba (state of Paraná, Brazil) treated successfully with miltefosine.
Topics: Animals; Brazil; Dog Diseases; Dogs; Female; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2023 |
Effective immuno-therapeutic treatment of Canine Leishmaniasis.
Topics: Animals; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral | 2023 |
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; | 2023 |
Rational repurposing, synthesis,
Topics: Chromones; Humans; Leishmania donovani; Leishmaniasis, Visceral | 2023 |
In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis.
Topics: Amphotericin B; Antiprotozoal Agents; Chronic Disease; Humans; Leishmania; Leishmaniasis; Leishmania | 2023 |
Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Synergism; Drug Therapy, Combination; Host-Paras | 2019 |
Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis.
Topics: Analysis of Variance; Animals; Antiprotozoal Agents; Drug Resistance; Female; Inhibitory Concentrati | 2019 |
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Topics: Adolescent; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Drug Ther | 2019 |
Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India.
Topics: Adult; Antiprotozoal Agents; Child; Eye Diseases; Female; Humans; India; Leishmaniasis, Visceral; Ma | 2020 |
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; DNA, Protozoan; Drug Therapy, Combin | 2020 |
Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
Topics: Acclimatization; Animals; Antiprotozoal Agents; Drug Resistance; Humans; Insect Vectors; Leishmania | 2020 |
Advanced case of PKDL due to delayed treatment: A rare case report.
Topics: Antiprotozoal Agents; Humans; India; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, V | 2020 |
Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dietary Supplements; Disease Models, Animal; Female; Glutamine; Human | 2020 |
Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma.
Topics: Aged; Antiprotozoal Agents; Combined Modality Therapy; Drug Substitution; Endemic Diseases; Humans; | 2020 |
Comparative evaluation of nucleic acid stabilizing reagents for RNA- and DNA-based Leishmania detection in blood as proxy for visceral burdens.
Topics: Animals; Cricetinae; Disease Models, Animal; DNA; DNA, Kinetoplast; Female; Humans; Indicators and R | 2020 |
Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Genes, Protozoan; Insect Vectors; Leishmania infantu | 2020 |
LEISHMANICIDAL ACTIVITY in vivo OF A MILTEFOSINE DERIVATIVE IN Mesocricetus auratus.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cytokines; Leishmania infantum; Leishmaniasis, Visceral; | 2020 |
Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Cytokines; Dog Diseases; Dogs; Drug Therapy, Combination | 2020 |
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line; Emulsions; Leishmania donovani; Leishmania | 2020 |
Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.
Topics: Adult; Africa, Eastern; Antiprotozoal Agents; Child; Humans; Leishmaniasis, Visceral; Phosphorylchol | 2020 |
Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
Topics: Albania; Amphotericin B; Antiprotozoal Agents; Fatal Outcome; Humans; Leishmania infantum; Leishmani | 2021 |
The drug resistance mechanisms in Leishmania donovani are independent of immunosuppression.
Topics: Amphotericin B; Animals; Antimony; Cytokines; Drug Resistance; Immunosuppression Therapy; Leishmania | 2021 |
Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Phosphorylcholine; | 2020 |
Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020).
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Combinations; D | 2021 |
Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Homeodomain Proteins; Huma | 2021 |
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
Topics: Acarbose; Animals; Antiprotozoal Agents; Drug Repositioning; Female; Immunity; Leishmania infantum; | 2021 |
Oral combination of eugenol oleate and miltefosine induce immune response during experimental visceral leishmaniasis through nitric oxide generation with advanced cytokine demand.
Topics: Administration, Oral; Animals; Cell Death; Cell Proliferation; Cytokines; Drug Interactions; Drug Th | 2021 |
Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Gene Expression Regulation; Interferon-gamma; Killer | 2021 |
Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Drug Resistance, Multiple; Drug Therapy, Combination; Fem | 2017 |
Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine.
Topics: Amphotericin B; Antiprotozoal Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Leishm | 2017 |
Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Fluorometry; Humans; Leishmania donovani; Leishmania | 2017 |
Risk Factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India.
Topics: Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Female; Health Facilities; Humans; India; Le | 2017 |
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Topics: Amphotericin B; Antiprotozoal Agents; Biopsy; Female; Humans; Immunocompromised Host; Leishmania; Le | 2017 |
Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.
Topics: Antiprotozoal Agents; Biomarkers; Cytokines; Drug Resistance; Gene Expression Regulation; Genes, Hel | 2017 |
Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Asymptomatic Infections; Biopsy; DNA, Inter | 2018 |
Case Report: Old World Mucosal Leishmaniasis: Report of Five Imported Cases to the Hospital for Tropical Diseases, London, United Kingdom.
Topics: Aged; Antiprotozoal Agents; Female; Humans; Immunosuppressive Agents; Leishmania infantum; Leishmani | 2017 |
Functional Involvement of Leishmania donovani Tryparedoxin Peroxidases during Infection and Drug Treatment.
Topics: Animals; Antimony Potassium Tartrate; Cytosol; Drug Resistance; Female; Host-Parasite Interactions; | 2018 |
Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.
Topics: Antiprotozoal Agents; Apoptosis; Benzoates; Cell Line, Tumor; Humans; Inhibitory Concentration 50; L | 2018 |
Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania infantum; Leishmaniasis, V | 2018 |
In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Topics: Amino Acid Sequence; Amphotericin B; Animals; Antiprotozoal Agents; Arginase; Benzimidazoles; Cell L | 2018 |
Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis.
Topics: Antiprotozoal Agents; Biomarkers; Biopsy, Needle; Calpain; Humans; Leishmania donovani; Leishmaniasi | 2018 |
Complex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine.
Topics: Antiprotozoal Agents; Ergosterol; Humans; Leishmania donovani; Leishmania major; Leishmaniasis, Visc | 2018 |
Effects of nanoemulsions prepared with essential oils of copaiba- and andiroba against Leishmania infantum and Leishmania amazonensis infections.
Topics: Animals; Antiprotozoal Agents; Emulsions; Fabaceae; Female; Gas Chromatography-Mass Spectrometry; In | 2018 |
First report of Leishmania infantum infection in the endangered orangutan (Pongo pygmaeus pygmaeus) in Madrid, Spain.
Topics: Allopurinol; Animals; Diagnosis, Differential; Disease Outbreaks; Endangered Species; Female; Leishm | 2018 |
Lactoferrin-modified Betulinic Acid-loaded PLGA nanoparticles are strong anti-leishmanials.
Topics: Amphotericin B; Animals; Anti-Inflammatory Agents; Antiparasitic Agents; Betulinic Acid; Cytokines; | 2018 |
The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; Ethiopia; Femal | 2018 |
Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Female; Leishmania infantum; Leishmaniasis, Visceral; Mal | 2018 |
Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Survival; Disease Models, Animal; Drug Synergism | 2018 |
Importance of secondary screening with clinical isolates for anti-leishmania drug discovery.
Topics: Antiprotozoal Agents; Drug Discovery; Drug Resistance; Humans; Leishmania donovani; Leishmaniasis, V | 2018 |
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Bangladesh; Fema | 2018 |
Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment.
Topics: Adolescent; Adult; Antiprotozoal Agents; Bangladesh; Humans; Keratitis; Leishmaniasis, Cutaneous; Le | 2018 |
A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.
Topics: Antiprotozoal Agents; Brazil; Computational Biology; DNA Copy Number Variations; Genetic Markers; Ge | 2018 |
New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
Topics: Antiprotozoal Agents; Brazil; Drug Resistance; Genes, Protozoan; Humans; Leishmania infantum; Leishm | 2018 |
Miltefosine enhances the fitness of a non-virulent drug-resistant Leishmania infantum strain.
Topics: Animals; Female; Genetic Fitness; Immunosuppression Therapy; Leishmania infantum; Leishmaniasis, Vis | 2019 |
Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.
Topics: Animals; Antiprotozoal Agents; CD4-Positive T-Lymphocytes; Cricetinae; Cyclophosphamide; Drug Resist | 2019 |
Eliminating visceral leishmaniasis in South Asia: the road ahead.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Bangladesh; Disease Vectors; Drug Therapy, Combinatio | 2019 |
Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Insect Vectors; Lei | 2019 |
A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Discovery; Female; Leishmania infantum; | 2019 |
Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
Topics: Acute-Phase Proteins; Allopurinol; Animals; Antiprotozoal Agents; Aryldialkylphosphatase; Dog Diseas | 2019 |
Visceral leishmaniasis in a patient with systemic lupus erythematosus from Colombia, Latin America.
Topics: Adult; Antiprotozoal Agents; Colombia; Humans; Leishmaniasis, Visceral; Lupus Erythematosus, Systemi | 2019 |
Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh.
Topics: Adolescent; Antiprotozoal Agents; Bangladesh; Fertility; Humans; Infertility, Male; Leishmaniasis, C | 2019 |
What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?
Topics: Antiprotozoal Agents; Clinical Protocols; Communicable Disease Control; Drug Resistance, Microbial; | 2013 |
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; K | 2013 |
Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project.
Topics: Amphotericin B; Antiprotozoal Agents; Cohort Studies; Data Collection; Female; Humans; India; Leishm | 2013 |
Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients.
Topics: Adolescent; Adult; Cells, Cultured; Child; Enzyme-Linked Immunosorbent Assay; Female; Fluorometry; G | 2013 |
In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Deoxycholic Acid; Disease Reservoirs; Do | 2013 |
Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
Topics: Adult; Antiprotozoal Agents; Bangladesh; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; | 2013 |
One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India.
Topics: Antiprotozoal Agents; Child; Follow-Up Studies; Humans; India; Leishmaniasis, Visceral; Male; Phosph | 2013 |
Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Topics: Adenosine Triphosphate; Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Cytochromes c; Dose-Res | 2013 |
In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine | 2013 |
Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
Topics: Amphotericin B; Antiprotozoal Agents; DNA, Protozoan; Drug Therapy, Combination; Humans; Leishmanias | 2014 |
Translating immune cell cross-talk into a treatment opportunity for visceral leishmaniasis.
Topics: Animals; Cell Communication; Humans; Immunity, Cellular; Immunotherapy; Interferon-gamma; Interleuki | 2013 |
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Topics: Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; Recur | 2013 |
Combination therapy with nitazoxanide and amphotericin B, Glucantime®, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes.
Topics: Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Combinations; Leishmania infant | 2014 |
Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Blood Chemical Analysis; Child; Child, Preschool; Chr | 2014 |
Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Enzyme-Linked Immunosorbent Assay; Im | 2014 |
Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Coinfection; HIV | 2014 |
Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Topics: Adolescent; Adult; Age Factors; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; India | 2014 |
Development of antileishmanial lipid nanocomplexes.
Topics: Administration, Oral; Amphotericin B; Antiprotozoal Agents; Calcium; Cholesterol; Circular Dichroism | 2014 |
The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Drug Resistance; Glutamate-Cysteine Ligase; | 2014 |
Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Topics: Animals; Antimony; Antiprotozoal Agents; Cricetinae; Humans; India; Leishmania infantum; Leishmanias | 2015 |
Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum.
Topics: Antiprotozoal Agents; Drug Evaluation, Preclinical; Drug Resistance; Humans; Leishmania infantum; Le | 2015 |
Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
Topics: Animals; Antibodies, Monoclonal; Antigens, Protozoan; Antiprotozoal Agents; CD4-Positive T-Lymphocyt | 2015 |
In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Resistance; Female; Leishman | 2015 |
Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Cytokines; Leishmaniasis, Visceral; Leptin; Macropha | 2015 |
Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Amphotericin B; Coinfection; D | 2015 |
Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmania donovani; Leishmaniasis, Visceral; Nepal; | 2015 |
PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; C | 2015 |
Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Topics: Adult; Antiprotozoal Agents; Child; Female; Histocytochemistry; Humans; India; Leishmaniasis, Cutane | 2015 |
A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Topics: Adolescent; Adult; Amphotericin B; Antibodies, Protozoan; Antimony Sodium Gluconate; Antiprotozoal A | 2016 |
Development of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis.
Topics: Animals; Cricetinae; Drug Delivery Systems; Lactic Acid; Leishmania donovani; Leishmaniasis, Viscera | 2016 |
In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
Topics: Animals; Antimony; Antiprotozoal Agents; Drug Resistance; Female; Leishmania donovani; Leishmaniasis | 2016 |
15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Apoptosis; Cell Line; Cricetulus; Disease Models, Ani | 2016 |
Treatment of visceral leishmaniasis: options and choice.
Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2016 |
A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Femal | 2016 |
Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania i | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Co | 2016 |
Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Topics: Antiprotozoal Agents; Coinfection; HIV Infections; Humans; Immunocompromised Host; Leishmania infant | 2016 |
Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
Topics: Animals; Cricetinae; Disease Models, Animal; Female; Leishmania donovani; Leishmania infantum; Leish | 2016 |
Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiprotozoal Agents; Aspartate | 2016 |
Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; DNA, Protozoan; Female; Humans; Leishmania donovani; Leishm | 2016 |
Nodular granulomatous glossitis as the sole clinical sign in canine leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Fluoresce | 2016 |
Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
Topics: Adult; Aged; Amphotericin B; Antiprotozoal Agents; Humans; Immunocompromised Host; Incidence; Kidney | 2017 |
Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Curcumin; Disea | 2017 |
Elimination of Kala-Azar from the Southeast Asia Region.
Topics: Animals; Antiprotozoal Agents; Bangladesh; Humans; India; Insect Control; Insect Vectors; Insecticid | 2017 |
Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Topics: Adult; Antiprotozoal Agents; Chemoprevention; HIV Infections; Humans; Leishmaniasis, Visceral; Male; | 2008 |
Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis.
Topics: Adolescent; Animals; Antiprotozoal Agents; Clofazimine; Diagnosis, Differential; Humans; Hypopigment | 2008 |
Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
Topics: Adolescent; Amphotericin B; Animals; Antiprotozoal Agents; Female; Humans; Interferon-gamma; Iran; L | 2008 |
Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Models, Animal; Disease Reservoirs; Dog Diseases | 2009 |
Interferon-gamma (INF-gamma), IL4 expression levels and Leishmania DNA load as prognostic markers for monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Biomarkers; DNA, Protozoan; Dog Diseases; Dogs; Interfer | 2008 |
Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antiparasitic Ag | 2008 |
Leishmania DNA quantification by real-time PCR in naturally infected dogs treated with miltefosine.
Topics: Animals; Base Sequence; DNA Primers; DNA, Protozoan; Dogs; Leishmania; Leishmaniasis, Visceral; Phos | 2008 |
Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
Topics: Adolescent; Adult; Age Distribution; Aged; Amphotericin B; Anthropometry; Antiprotozoal Agents; Body | 2009 |
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Dermatitis; Humans; Leishmaniasis, Cutaneous; Leishmani | 2009 |
Newer strategies for the kala-azar elimination programme in India.
Topics: Amphotericin B; Data Collection; Humans; India; Information Dissemination; Leishmaniasis, Visceral; | 2009 |
Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Male; Nepal; Phosphorylcholine; Recurrence; T | 2009 |
Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Topics: Animals; Antiprotozoal Agents; Immunity; Interferon gamma Receptor; Interferon-gamma; Leishmania don | 2009 |
Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
Topics: Administration, Oral; Amphotericin B; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Dose | 2009 |
Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Cost-Benefit Analysis; Direct Servic | 2009 |
Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Topics: Adult; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Biopsy; Female; Humans; Leis | 2009 |
CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cytokines; Drug Synergism; Female; Hydrogen Peroxide; Imm | 2010 |
Use of miltefosine in the treatment of visceral leishmaniasis in children at a tertiary care hospital of Karachi.
Topics: Administration, Oral; Antiprotozoal Agents; Child; Hospitals, University; Humans; Infant; Leishmania | 2010 |
Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Diffuse Cutaneous; Leishmaniasis, Viscer | 2010 |
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias | 2010 |
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
Topics: Amphotericin B; Antiprotozoal Agents; Bangladesh; Cost-Benefit Analysis; Drug Therapy, Combination; | 2010 |
Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cinnamates; Cricetinae; Disease Models, Animal; D | 2011 |
Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; India; Leishmania | 2010 |
Ambisome plus miltefosine for Indian patients with kala-azar.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Child; Child, P | 2011 |
Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis.
Topics: Adolescent; Adult; Aged; Animals; Antimony Potassium Tartrate; Antiprotozoal Agents; Benzoates; Fema | 2011 |
Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.
Topics: Animals; Antiprotozoal Agents; Cinnamates; Cricetinae; Drug Therapy, Combination; Fluconazole; Glyco | 2011 |
Combination therapy for visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combination; Human | 2011 |
CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.
Topics: Animals; Cricetinae; Drug Combinations; Female; Leishmaniasis, Visceral; Male; Mice; Mice, Inbred BA | 2011 |
Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Dose-Response Relationship, Drug; Dru | 2011 |
Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil.
Topics: Animals; Antiprotozoal Agents; Brazil; Dog Diseases; Dogs; Immunoglobulin G; Leishmania infantum; Le | 2011 |
Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Topics: Animals; Antiprotozoal Agents; Cinnamates; Cricetinae; Disease Models, Animal; Drug Therapy, Combina | 2011 |
A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Drug Resistance, Multiple; Drug Therapy, Combination; H | 2011 |
Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro.
Topics: Animals; Antiprotozoal Agents; Drug Evaluation, Preclinical; Female; Leishmania infantum; Leishmania | 2011 |
Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; B7-1 Antigen; B7-2 Antigen; Child; Cytokines; Female; | 2011 |
Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cysteine; Female; Leishmaniasis, Visceral; Lipoproteins; | 2011 |
Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.
Topics: Antiprotozoal Agents; Chromatography, High Pressure Liquid; Humans; Leishmania donovani; Leishmanias | 2012 |
Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Disease Models, Anim | 2011 |
Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Cell Proliferation; Cricetinae; Cytokines; Dis | 2012 |
Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Synergism; Fluoroquinolones; Le | 2012 |
Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.
Topics: Adult; Antiprotozoal Agents; Cell Line; Cytokines; Female; Humans; Leishmania donovani; Leishmaniasi | 2012 |
Leishmania strains causing self-healing cutaneous leishmaniasis have greater susceptibility towards oxidative stress.
Topics: Antimony; Free Radicals; Humans; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral | 2012 |
Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2012 |
Leishmania resistance to miltefosine associated with genetic marker.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Female; Humans; Inhibitory Concentration 50; | 2012 |
[Exotic imported disease and scourge of the poor].
Topics: Antiprotozoal Agents; Child, Preschool; Developing Countries; Diagnosis, Differential; Humans; Insec | 2012 |
Development of splenic marginal zone lymphoma in a HIV-negative patient with visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Bone Marrow; HIV; HIV Infections; Humans; Immunophenotyping; K | 2012 |
Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Contraceptive Agents; Female; Humans; India; Leish | 2012 |
Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Cytokines; Dose-Response Relationship, Drug; Drug Therapy | 2012 |
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Female; Humans; India; Inhibitory Concentra | 2012 |
A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal.
Topics: Antiprotozoal Agents; Bangladesh; Drugs, Generic; Humans; Leishmaniasis, Visceral; Neglected Disease | 2012 |
Real-time PCR to quantify Leishmania donovani in hamsters.
Topics: Amidines; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; DNA, Kinetoplast; Dose- | 2013 |
Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Cell Culture Techniques; Cell Survival; Inhibitory C | 2012 |
Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.
Topics: Animals; Antiprotozoal Agents; Communicable Disease Control; Health Services Accessibility; Humans; | 2012 |
Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Clinical Trials, Phase III as Topic; Cohort Studies; | 2013 |
A series of case reports of autochthonous visceral leishmaniasis, mostly in non-endemic hilly areas of Nepal.
Topics: Adolescent; Adult; Aged; Amphotericin B; Child; Child, Preschool; Dose-Response Relationship, Drug; | 2013 |
New therapy for visceral leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Humans; India; Leishmaniasis, Visceral; Phosphorylcholin | 2002 |
Miltefosine presents new hope for leishmaniasis patients.
Topics: Antiprotozoal Agents; Government Programs; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine | 2002 |
Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis.
Topics: Adult; Animals; Antibodies, Protozoan; Antibody Formation; Antigens, Protozoan; Antimony Sodium Gluc | 2002 |
An oral drug for leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Clinical Trials as Topic; Humans; India; Leishmaniasis, | 2002 |
Kala-azar--progress against a neglected disease.
Topics: Administration, Oral; Antiprotozoal Agents; Endemic Diseases; Leishmaniasis, Visceral; Phosphorylcho | 2002 |
Miltefosine in visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Fertility; Humans; Leishmaniasis, Visceral; Male; Phosphorylcholine | 2003 |
Miltefosine for Indian visceral leishmaniasis.
Topics: Antiprotozoal Agents; Hemorrhage; HIV Infections; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2003 |
Miltefosine for Indian visceral leishmaniasis.
Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Phosphorylcholine; Research D | 2003 |
The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Buthionine Sulfoximine; Drug Resistance; Female; | 2003 |
New therapy for "black fever" is 95% effective: India licenses the first oral drug for visceral leishmaniasis, a lethal disease of poverty.
Topics: Administration, Oral; Antiprotozoal Agents; Drug Approval; Humans; India; Leishmaniasis, Visceral; P | 2002 |
Breakthrough in the management of visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; India; Leishmania donovani; Leishm | 2003 |
Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Cell Division; Coloring Agents; Cricetinae; Cricetulus; DN | 2004 |
Short report: fluorescent Leishmania: application to anti-leishmanial drug testing.
Topics: Animals; Antiprotozoal Agents; Flow Cytometry; Green Fluorescent Proteins; Humans; Leishmania donova | 2004 |
[Leishmaniasis--oral treatment with hexadecylphosphocholine].
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Resistance; | 2004 |
Efficacy of Desmodium gangeticum extract and its fractions against experimental visceral leishmaniasis.
Topics: 1-Butanol; Administration, Oral; Animals; Chloroform; Cricetinae; Drug Administration Schedule; Drug | 2005 |
Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; L | 2005 |
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Line; Cricetinae; Dis | 2005 |
Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis.
Topics: Adjuvants, Immunologic; Animals; Antiprotozoal Agents; Biopsy; Cinnamates; Cricetinae; Drug Interact | 2005 |
Availability of miltefosine for the treatment of kala-azar in India.
Topics: Antiprotozoal Agents; Humans; India; Leishmaniasis, Visceral; Phosphorylcholine; Poverty | 2005 |
Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
Topics: Animals; Antiprotozoal Agents; Cell Membrane; Drug Resistance; Fatty Acids; Humans; Leishmania donov | 2005 |
Challenges in the management of visceral leishmaniasis.
Topics: Amebicides; Amphotericin B; Antimony Sodium Gluconate; Antiparasitic Agents; Antiprotozoal Agents; E | 2005 |
The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Humans; Leishmania; Leishmaniasis, Cutaneous; Leishm | 2005 |
Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Topics: Adult; Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Europe; Germany; HI | 2006 |
Development of a semi-automated colorimetric assay for screening anti-leishmanial agents.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Colorimetry; Drug Evaluation, Preclinical; Humans; In | 2006 |
Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Topics: Administration, Oral; Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Injections, In | 2006 |
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cricetinae; Drug Synergism; Leishmania donovani; Leis | 2006 |
Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
Topics: Administration, Oral; Adult; Anti-Retroviral Agents; Antiprotozoal Agents; Drug Therapy, Combination | 2006 |
Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
Topics: Administration, Oral; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Viscera | 2006 |
Miltefosine in children with visceral leishmaniasis.
Topics: Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmaniasis, Visceral; Male; Phosph | 2006 |
Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Cost-Benefit Analysis; Decision Trees; Deoxycholic A | 2007 |
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Topics: Adenosine Triphosphatases; Animals; Antiprotozoal Agents; Drug Resistance; Female; Genotype; Leishma | 2007 |
Wilson disease with visceral leishmaniasis: an extremely uncommon presentation.
Topics: Adolescent; Chelating Agents; Hepatolenticular Degeneration; Humans; Leishmaniasis, Visceral; Male; | 2007 |
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Bone Marrow; Female; HI | 2008 |
Miltefosine in the treatment of a case of visceral leishmaniasis with renal dysfunction.
Topics: Administration, Oral; Antiprotozoal Agents; Humans; India; Leishmaniasis, Visceral; Male; Middle Age | 2007 |
Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine.
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Female; Humans; Leishmaniasis, V | 2007 |
Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Phosph | 2008 |
HIV infection, visceral leishmaniasis and Guillain-Barré syndrome in the same patient: a case report.
Topics: Adult; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; Guillain-Barre Syndro | 2008 |
Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII.
Topics: Animals; Antimony Potassium Tartrate; Cosmids; Drug Resistance; Leishmania infantum; Leishmaniasis, | 2008 |
Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine.
Topics: Administration, Topical; Animals; Antifungal Agents; Child, Preschool; Female; Humans; Leishmania in | 2008 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Lei | 1996 |
Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.
Topics: Animals; Antiprotozoal Agents; Female; Leishmania infantum; Leishmaniasis, Visceral; Mice; Mice, Inb | 1998 |
[Visceral leishmaniasis: a new oral treatment?].
Topics: Antiprotozoal Agents; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; | 1999 |
Miltefosine--the long-awaited therapy for visceral leishmaniasis?
Topics: Administration, Oral; Antiprotozoal Agents; Female; Gastrointestinal Diseases; Humans; Leishmaniasis | 1999 |
Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
Topics: Animals; Antiprotozoal Agents; Leishmania donovani; Leishmaniasis, Visceral; Macrophage Activation; | 2000 |
Miltefosine for visceral leishmaniasis.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Phosphorylcholine | 2000 |
Miltefosine for visceral leishmaniasis.
Topics: Administration, Oral; Aminoquinolines; Antiprotozoal Agents; Drug Synergism; Humans; Leishmaniasis, | 2000 |
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania donovani; Le | 2000 |
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Leishmania donovani; Leish | 2001 |
Drug resistance in Indian visceral leishmaniasis.
Topics: Aminoquinolines; Amphotericin B; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; D | 2001 |
Miltefosine Zentaris.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Administration Schedule; Humans; Leish | 2002 |
Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice.
Topics: Administration, Oral; Animals; Antimony Sodium Gluconate; Bone Marrow; Female; Leishmania; Leishmani | 1992 |